POPULARITY
Categories
515 episodes with cityscapes
359 episodes with cityscapes
209 episodes with cityscapes
22 episodes with cityscapes
9 episodes with cityscapes
4 episodes with cityscapes
9 episodes with cityscapes
3 episodes with cityscapes
2 episodes with cityscapes
Beyond The Outer Realm welcomes special Guest, Luke Eastwood Host: Michelle Desrochers Date: April 8th, 2025 Episode: 546 Discussion : Luke will be discussing his new book " Scotia: The Lost Sister of Tutankhamun" From Luke's Press Release: - This is the latest book from author, folklorist and amateur historian Luke Eastwood, who has previously had success with titles such as “Kerry Folk Tales”, “Dingle Folk Tales” and “The Druid's Primer”. It also features an introduction from best-selling UK author and acclaimed archaeologist Lorraine Evans. A nation under threat and a dynasty facing collapse under a much hated, heretic king. Tracing the Amarna Egyptian royal family, from Akhenaten through to Tutankhamun and the final Pharaoh Horemheb, a picture emerges of a dynasty caught up in a religious controversy and the unfolding of an unstoppable drama. This book explores the mysterious deaths of this dynasty's pharaohs and the flight of one of its last queens, an older sister of the ill-fated Tutankhamun. Why did she flee Egypt and how? Why did she go to Spain and then Scotland? How did she come to meet her death in the West of Ireland? Contact for the show - theouterrealmcontact@gmail.com Rumble: TheOuterRealm X - MicheleDerocher Website: www.theouterrealmradio.com Please support us by Liking, Subscribing, Sharing and Commenting. Thank you all !!! About Luke: I have been involved in the arts in some shape or form since I was a teenager. I was born in Aberdeen, Scotland but spent most of my childhood and all my teenage years in Kent and Surrey, England. At 19 I moved to London to study at university and this was the beginning of my development into a semi-professional or professional artist, designer, musician, photographer and writer. In 1990, at university, I discovered the Apple MacIntosh computer which I immediately fell in love with, leading to my interest in digital art and Graphic Design (which became my career), following a stint in Mitre House Publishing for my degree industrial placement and writing for the university magazine Cityscape. I began writing poetry at the age of 15, pretty badly I might add. Over time I developed my own style of both poetry and prose. My first article was published in 1991 but a year after leaving university I left journalism aside for other activities (mainly music) until the early 2000s when I began to write more frequently. For most of the 1990s I concentrated on my band Children Of Dub and released several albums and singles during that time. A multitude of my articles in magazines and websites have been appearing in recent years, which you can find on my articles page. In 2005 my first book, on spiritual wisdom, "The Journey" was published under the pseudonym Joseph Dawton. In 2006 I was editor of a collection of poetry entitled "Where The Hazel Falls", featuring some of my poems, as well as eight other authors in Ireland.
When a city proposes zoning changes, how do you know whether they'll be effective? Aaron Barrall shares how we approached the problem in Los Angeles, with lessons for similar upzoning efforts around the world.Show notes:Barrall, A., & Phillips, S. (2024). CHIPing In: Evaluating the effects of LA's Citywide Housing Incentive Program on neighborhood development potential. UCLA Lewis Center for Regional Policy Studies.YouTube recording of Aaron's and Shane's presentation at UCLA on the report's findings.Monkkonen, P., Manville, M., Lens, M., Barrall, A., & Arena, O. (2023). California's Strengthened Housing Element Law: Early Evidence on Higher Housing Targets and Rezoning. Cityscape, 25(2), 119-142.Elmendorf, C. S., Biber, E., Monkkonen, P., & O'Neill, M. (2020). Making It Work: Legal Foundations for Administrative Reform of California's Housing Framework. Ecology Law Quarterly, 47(4), 973-1060.Episode 59 of UCLA Housing Voice: The Costs of Discretion with Paavo Monkkonen and Mike Manville.Episode 79 of UCLA Housing Voice: Who Pays For Inclusionary Zoning with Shane Phillips.
Fluent Fiction - Hungarian: From Cityscape to Countryside: Zoltán's Easter Treasure Quest Find the full episode transcript, vocabulary words, and more:fluentfiction.com/hu/episode/2025-04-02-22-34-02-hu Story Transcript:Hu: A tavaszi nap sugarai gyengéden simogatták a magyar vidék földjét.En: The gentle rays of the spring sun caressed the land of the magyar countryside.Hu: Zoltán, a harmincas éveinek végén járó férfi, lassan sétált a frissen zöldellő mezők között, élvezve a természet csendjét és a madarak énekét.En: Zoltán, a man in his late thirties, walked slowly among the freshly greened fields, enjoying the silence of nature and the song of the birds.Hu: Nemrég költözött ide a nyüzsgő városi élet elől menekülve, de a kíváncsiság és a kalandvágy nem hagyta nyugodni.En: He had recently moved here to escape the bustling city life, but curiosity and a thirst for adventure would not let him rest.Hu: Egy régi öreg fa mellett megállt, hogy pihenjen egy kicsit.En: He stopped beside an old, ancient tree to take a break.Hu: Ahogy a fatörzsre támaszkodott, valami különöst érzett.En: As he leaned against the tree trunk, he felt something unusual.Hu: A fa kérge mögött egy kis rés rejtőzött, melyben egy kopott, megsárgult levél rejtőzködött.En: Behind the bark, there was a small crevice hiding a tattered, yellowed letter.Hu: Óvatosan kihúzta és szívverése felgyorsult a titokzatos felfedezéstől.En: He carefully pulled it out, his heartbeat quickening with the mysterious discovery.Hu: Zoltán hazafelé tartva elmerült a gondolataiban.En: Heading home, Zoltán became lost in thought.Hu: A levél régi magyar nyelven íródott, és ő alig értette.En: The letter was written in old Hungarian, and he understood little of it.Hu: Tudta, hogy segítségre lesz szüksége.En: He knew he would need help.Hu: Másnap megkereste Kata-t, a szomszédját, aki a magyar vidék történeteit szinte szívből ismerte.En: The next day, he sought out Kata, his neighbor, who seemed to know the stories of the Hungarian countryside by heart.Hu: Kata vonakodott egy idegen előtt megnyitni családi meséit, de Zoltán kíváncsisága és őszinte érdeklődése végül meggyőzte őt.En: Kata hesitated to open her family's tales to a stranger, but Zoltán's curiosity and genuine interest eventually convinced her.Hu: A húsvét közeledtével a falut áthatotta a készülődés izgalma.En: As Easter approached, the village was infused with the excitement of preparations.Hu: A templom harangjai, a puha kalács illata és a locsolkodás hagyománya mind hozzájárultak a vidám ünnepi hangulathoz.En: The church bells, the scent of soft kalács (a type of bread), and the tradition of sprinkling all contributed to the cheerful festive atmosphere.Hu: Zoltán és Kata a takaros látványra függesztették tekintetüket, miközben együtt próbálták kibogozni a levél titkát.En: Zoltán and Kata focused their gaze on the charming scene while they tried to unravel the letter's secret together.Hu: Hosszú órák és számtalan csésze tea után végre sikerrel jártak.En: After long hours and countless cups of tea, they finally succeeded.Hu: A levél egy régi rejtély nyomait tartalmazta, mely kapcsolatban állt Lászlóval, a faluszélén élő idős férfival.En: The letter contained traces of an old mystery related to László, an elderly man living on the edge of the village.Hu: Az írás szerint egy eldugott kincs várja megtalálóját, és László családjához kötődik.En: According to the writing, a hidden treasure awaited discovery, connected to László's family.Hu: Zoltán és Kata bizonytalanul, de elszántan kopogtak László ajtaján.En: Zoltán and Kata, uncertain but determined, knocked on László's door.Hu: Az idős ember eleinte zárkózott volt, de amikor megtudta, hogy a kincs története újra életre kelhet, csillogást láttak a szemében.En: The elderly man was initially reserved, but when he learned that the story of the treasure might come alive again, they saw a sparkle in his eyes.Hu: Együtt indultak útnak.En: They set out together.Hu: Az úthoz vezető ösvényt frissen nyíló vadvirágok szegélyezték.En: The path leading to their journey was lined with freshly blooming wildflowers.Hu: A falu határán lévő erdő mélyén végül megtalálták a kincsesládát, mely nem aranyat vagy ezüstöt, hanem egy régi időkből származó időkapszulát rejtett.En: Deep in the forest at the village boundary, they finally found the treasure chest, which did not hide gold or silver but rather a time capsule from a bygone era.Hu: Az emlékek és régi tárgyak közösséget kovácsoltak a falu lakóiban és Zoltán így az igaz kincsre lelt: a közösség meleg ölelésére.En: The memories and old objects forged a bond among the villagers, and Zoltán thus found the true treasure: the warm embrace of community.Hu: Zoltán most egyike volt a közösségnek.En: Zoltán was now one of the community.Hu: A tavaszi nap sugarában állva, új barátokkal körülvéve érezte, hogy a kaland igazi értelme az út, ami az emberekhez vezet.En: Standing in the rays of the spring sun, surrounded by new friends, he felt that the true value of adventure lies in the path that leads to people.Hu: Kata oldalán állva, mosolyogva nézte az összegyűlt falusiakat.En: Standing by Kata's side, he smiled as he looked at the gathered villagers.Hu: A húsvét öröme és az újonnan talált kötelékek megszilárdították Zoltán helyét a falu szívében, és elhozta neki mindazt, amire mindig is vágyott: kalandot, felfedezést és igazi, emberi kapcsolódást.En: The joy of Easter and the newly found bonds solidified Zoltán's place in the heart of the village and brought him everything he had always desired: adventure, discovery, and genuine human connections. Vocabulary Words:rays: sugaraicaressed: simogattákbustling: nyüzsgőcrevice: réstattered: kopottyellowed: megsárgultcuriosity: kíváncsisággenuine: őszintefestive: ünnepiunravel: kibogoznidetermined: elszántreserved: zárkózottsparkle: csillogáspath: útblooming: nyílóboundary: határcapsule: időkapszulaforged: kovácsoltakbond: közösségadventure: kalandtreasure: kincsembrace: öleléselderly: idősletter: levélthirst: szomjúságtrunk: fatörzsinfused: áthatottascent: illatgaze: tekintetétmemories: emlékek
About: Looking out into the nighttime city, you'll find a cityscape of lively lights and so much potential. Artwork: Streets of Rage 00:00 - The Street of Rage [Streets of Rage] by Yuzo Koshiro > 01:59 - The Dark City [The Revenge Of Shinobi] by Yuzo Koshiro > 03:04 - Nocturne [FEZ] by Disasterpeace > 05:11 - The Lounge Where We Speak Of Tomorrow [Etrian Odyssey] by Yuzo Koshiro > 06:46 - Night Life [SimCity 3000] by Jerry Martin > 12:04 - The Port City Bathed In Twilight [Etrian Odyssey III: The Drowned City] by Yuzo Koshiro > 13:26 - Night Highway [Snowboard Kids] by Isao Kasai, Tomohiko Satou > 17:00 - Formations [FEZ] by Disasterpeace > 19:21 - Game Over [Snatcher] by Akira Yamaoka > 21:36 - Streets of Rage 4 Main Theme [Streets Of Rage 4] by Yuzo Koshiro > 25:30 - Tokyo -Twilight- [Shin Megami Tensei IV] by Ryota Kozuka, Toshiki Konishi, Kenichi Tsuchiya, Tsukasa Masuko, Shoji Meguro > 28:15 - Last Call [VA-11 HALL-A] by Garoad > pixelbeatpod@icloud.com >
It seemed like a normal day until you listened to the voice message from your friend. It sounded urgent and like their life was in danger. They wanted to meet you at this club. You tried to call them back to find out more, but nobody answered. You started to worry and fear the worst, but you plucked up your courage. You just wished there still was Neon Hope by Francesco Grothe and Dominik Schönleben from Hopeful Games with illustrations from Robert Herzig and Consuelo Pecchenino.Read the full review here: https://tabletopgamesblog.com/2025/02/15/neon-hope-saturday-review/Useful LinksNeon Hope: https://neonhopegame.com/Rulebook: https://neonhopegame.com/wp-content/uploads/2025/01/NEON-HOPE-Quickstart-Rules-A5-digital-V1.1.1.pdfKickstarter campaign: https://www.kickstarter.com/projects/hopefulgames/neon-hope-cyberpunk-meets-solarpunkHopeful Games: https://hopeful-games.com/BGG listing: https://boardgamegeek.com/boardgame/421246/neon-hopeAdventure Games: The Dungeon review: https://tabletopgamesblog.com/2022/06/25/adventure-games-the-dungeon-saturday-review/Pandemic review: https://tabletopgamesblog.com/2020/01/18/pandemic-saturday-review/MusicIntro Music: Bomber (Sting) by Riot (https://www.youtube.com/audiolibrary/)Music: "Cityscape" by AShamaluevMusic.Website: https://www.ashamaluevmusic.comMusic: "District" by AShamaluevMusic.Website: https://www.ashamaluevmusic.comMusic: "Megacity" by AShamaluevMusic.Website: https://www.ashamaluevmusic.comIf you want to support this podcast financially, please check out the links below:Patreon: https://www.patreon.com/tabletopgamesblogKo-Fi: https://ko-fi.com/TabletopGamesBlogWebsite: https://tabletopgamesblog.com/
Inspiring Architecture and Urban Design with Kevin KennonIn this episode of the Architecture and Innovation Podcast, host Tom DiOro interviews visionary architect Kevin Kennon, discussing his impactful career, significant projects including the World Trade Center Design Competition, and his perspectives on beauty and dignity in architecture. Kennon shares his experiences in designing across various urban landscapes and how trust plays a central role in client relationships. The conversation also delves into the future of architecture with the rise of AI and decentralized practices. The episode concludes with reflections on the importance of collaboration and gratitude for the contributions of colleagues.For more information visit:https://www.kdcaia.com/00:00 Introduction to Trust in Business00:43 Meet Kevin Kennon: Visionary Architect03:07 Kevin's World Trade Center Design Experience06:35 The Power of Architecture in Healing07:00 Exploring Beauty in Architecture09:58 The Concept of Dignity in Architecture16:19 The Impact of AI on Architecture21:07 Cityscapes and Urban Design24:15 Reflections and Gratitude
Join us as Andrew Conboy, an ISA certified arborist famously known as Andrew the Arborist, captivates us with his journey through urban forestry and ecological restoration. Andrew's passion for integrating native flora into cityscapes shines as he addresses the challenges of urban stressors like soil compaction and pollution. Explore how underutilized species such as swamp white oak and post oak offer hope for climate adaptation in urban areas. From historical anecdotes about the resilience of honey locusts to the intriguing notion of urban foraging, Andrew sheds light on the potential of trees to transform our cities. The heart of the episode beats with Andrew's insights on community-based environmental stewardship. Discover how the seeds of Colonial Canopy Trees were planted, nurturing a grassroots initiative to tackle invasive species and promote native tree planting. Andrew shares the power of starting small and the joy of building community connections, highlighting stories where volunteers bridge generational and cultural divides. His experiences illustrate that meaningful environmental change starts with local action and collaboration, with each tree planted and invasive weed pulled embodying a step toward a healthier ecosystem. This episode also ventures into the digital realm, where Andrew discusses the impact of long-form video content in raising awareness about native plants and urban forestry. Reflecting on his transition from a gaming content creator to an ecological educator, Andrew emphasizes the role of storytelling in engaging communities. As the conversation unfolds, listeners are invited to participate in environmental restoration efforts, understanding that the fusion of personal narratives and ecological action can truly reshape our urban landscapes. Check out Andrew's nonprofit, Colonial Canopy Trees, here: https://colonialcanopytrees.wordpress.com/ For sources, transcripts, and to read more about this subject, visit: www.agroecologies.org For sources, transcripts, and to read more about this subject, visit: www.agroecologies.org To support this podcast, join our patreon for early, commercial-free episode access at https://www.patreon.com/poorprolesalmanac For PPA Restoration Content, visit: www.restorationagroecology.com For PPA Merch, visit: www.poorproles.com For PPA Native Plants, visit: www.nativenurseries.org To hear Tomorrow, Today, our sister podcast, visit: www.tomorrowtodaypodcast.org/ Key Words: Urban Forestry, Ecological Restoration, Native Flora, Cityscapes, Urban Stressors, Soil Compaction, Pollution, Climate Adaptation, Invasive Species, Native Tree Planting, Community-Based Environmental Stewardship, Grassroots Initiative, Honey Locust, Urban Foraging, Digital Content, Environmental Education, Community Connections, Microvolunteering, Invasive Weed Management, Environmental Change
What if the honey locust tree holds the key to transforming American agriculture yet remains an untapped treasure? Join us as we explore this remarkable tree's profound historical significance and unique attributes. We guide you through its pre-human landscapes and symbiotic relationship with Pleistocene megafauna, shedding light on how its fearsome thorns might have served as tattoo tools for indigenous peoples. With insights from Dr. Robert Warren, we unravel the intriguing journey of the honey locust, drawing comparisons to the Kentucky coffee tree and pondering its adaptation to wet regions through human intervention. In a lighthearted and anecdotal manner, we delve into the quirky connections between anachronistic trees like the honey locust and Kentucky coffee tree, alongside their relationships with now-extinct species. Discover the indigenous significance of the honey locust's sweet pulp, a sugar alternative in warmer regions, and laugh with us as we draw amusing parallels with modern-day treats like candy corn. While we acknowledge the mysteries surrounding ancient methods of processing honey locust pulp, our light-hearted exploration invites you to imagine historical storage practices and potential uses. The honey locust is more than just a historical icon; it is a beacon of agricultural potential. Uncover its promising varieties, like Millwood, identified in the 1930s, and their potential for livestock feed and ethanol production. We recount the efforts of researchers like Dr. James Hanover to unlock the tree's capabilities for sustainable farming systems. Whether it's silvopasture or energy farming, the honey locust fits seamlessly into modern agriculture, offering ecological benefits and versatility. We invite you to join us in supporting ongoing research into this fascinating crop and perhaps even become a part of our knowledge-sharing community. For sources, transcripts, and to read more about this subject, visit: www.agroecologies.org To support this podcast, join our patreon for early, commercial-free episode access at https://www.patreon.com/poorprolesalmanac For PPA Restoration Content, visit: www.restorationagroecology.com For PPA Merch, visit: www.poorproles.com For PPA Native Plants, visit: www.nativenurseries.org To hear Tomorrow, Today, our sister podcast, visit: www.tomorrowtodaypodcast.org/ Key words: Urban Forestry, Ecological Restoration, Native Flora, Cityscapes, Urban Stressors, Soil Compaction, Pollution, Climate Adaptation, Invasive Species, Native Tree Planting, Community-Based Environmental Stewardship, Grassroots Initiative, Honey Locust, Urban Foraging, Digital Content, Environmental Education, Community Connections, Micro-volunteering, Invasive Weed Management, Environmental Change
Welcome to another enlightening episode of The Brand Called You!
Travelnews Online | Rebuilding Travel | Trending | eTurboNews
In today's episode Andy, Mike and Adam are very excited to chat to the amazing Verity Milligan about honing her craft as a multi award winning photographer, specialising in Landscapes and Cityscapes. We discuss 'that' poppy photo, her love of chasing light and capturing emotion, building atmosphere, drawing the viewer into her image and creativity in photography. Of course, as usual, we have some cracking topics of the week, weird world facts and some hilarious snapshot shenanigans!!!!
Cityscapes: Anthology of Urban Short Stories and Poems by B.W. WilliamsThe World Health Organization estimates that half of the world's population is currently living in cities and will continue to climb. Cities are often vilified in many stories as 'concrete jungles, slums, ' or seem terrifying to many. Thomas Jefferson believed that the strength and future of America lay in its rural heritage, and that cities were anathema to this concept. Perhaps the truth is that they are a culmination and reflection of the best and worst in our society. Cities are by their very nature, split personalities. Wasteful and ecoconscious. Chaotic in appearance, but concerned about efficiency, economies of scale, and marshalling the resources required to house, feed, clothe, educate, and move masses of people back and forth from home to work, and play. Many cities are also unique in that people gravitate toward them as centers of cultures and learning. The theme of this collection of urban short stories and poems revolve around life in the city during four seasons. In the section outlined, 'Spring, ' for example, I start with an ode to New York, a poem dedicated to the city and its vibrancy, celebrating the dawn of something new and fresh. In the 'Fall, ' section, on the other hand, I make historical reference to events of September 11th, 2001, in the poem Big Brothers. In between, the thematic expression of urban life and its experiences during the different seasons is laid out, sometimes metaphorically, as in the poem, 'Shadow of Wings, ' which represents summer travel and freedom from the routines of life, and at times literally, as is in the short story, 'South Station, ' where the main scene is played out in the winter.Berestrand Williams is a graduate of Harvard College and the University of Connecticut School of Medicine.He is employed by Mount Sinai Hospital in New York and is the Medical Director for the Mount Sinai-Unite Here Health Primary Care Center, which cares for the employees of the Atlantic City, New Jersey based casinos and their dependents.His interest in writing began in third grade when he wrote and acted out his first play about a detective in front of his class for show and tell.The critique was mixed, but undaunted he continued to write about events, politics, and sports through college, graduate school, to the present day, despite busy days and frequent sleepless nights.He has written poems and short stories about interesting situations and moments when people are at their worst, but also demonstrate remarkable strength and heroism.He resides with his family on the Jersey Shorehttps://www.amazon.com/Cityscapes-Anthology-Urban-short-stories/dp/166326550Xhttps://mainspringbooks.com/http://www.bluefunkbroadcasting.com/root/twia/101024bwwmsb.mp3
Cities have lived with exclusionary zoning for decades, if not generations. Is inclusionary zoning the answer? Inclusionary zoning, or IZ, requires developers to set aside a share of units in new buildings for low- or moderate-income households, seeking to increase the supply of affordable homes and integrate neighborhoods racially and socioeconomically. But how well does it accomplish these goals? This week we're joined by the Mercatus Center's Dr. Emily Hamilton to discuss her research on how IZ programs have impacted homebuilding and housing prices in the Washington, D.C. region, and the ironic reality that the success of inclusionary zoning relies on the continued existence of exclusionary zoning. Also, Shane and Mike rant about nexus studies. Originally aired in 2022.Show notes:Hamilton, E. (2021). Inclusionary zoning and housing market outcomes. Cityscape, 23(1), 161-194.Manville, M., & Osman, T. (2017). Motivations for growth revolts: Discretion and pretext as sources of development conflict. City & Community, 16(1), 66-85.Bento, A., Lowe, S., Knaap, G. J., & Chakraborty, A. (2009). Housing market effects of inclusionary zoning. Cityscape, 7-26.Li, F., & Guo, Z. (2022). How Does an Expansion of Mandatory Inclusionary Housing Affect Housing Supply? Evidence From London (UK). Journal of the American Planning Association, 88(1), 83-96.Schleicher, D. (2012). City unplanning. Yale Law Journal, 7(122), 1670-1737.Phillips, S. (2022). Building Up the" Zoning Buffer": Using Broad Upzones to Increase Housing Capacity Without Increasing Land Values. UCLA Lewis Center for Regional Policy Studies.Background on the inclusionary zoning program in Los Angeles (struck down in court, but later enabled by the state legislature).More on housing voucher policy in our interview with Rob Collinson.More on minimum lot size reform in our interview with M. Nolan Gray.A blog post questioning whether new market-rate housing actually “creates” demand for low-income housing.Los Angeles Affordable Housing Linkage Fee nexus study.
Get 25% off my Story Builders course by signing up before 1st October! https://easystoriesinenglish.com/build In today's episode, learn all about the second-largest city in Germany with the world's largest model railway, how I'm conquering my fears with a piece of paper, the controversial new smoking bans in the UK and my fabulous new course Story Builders! Go to EasyStoriesInEnglish.com/Hamburg for the full transcript. Mit dem Code easystories erhältst du das 12-Monatsabo von Babbel zumPreis von nur 6 Monaten. Das Angebot gilt bis zum 31. Oktober 2024. Einfach auf https://www.babbel.com/audio einlösen und loslegen. Get episodes without adverts + bonus episodes at EasyStoriesInEnglish.com/Support. Your support is appreciated! Vocabulary: ‘How did you find…?', Streak (record), Leafy, Suburb, Model railway, Nerd, Cityscape, VR, Overwhelmed, Demolish, Bulge out, Privilege, Cobbled, Mortar, Rest on your laurels, CV, Bubbly, Rejection, Trial shift, Bucket list, Resilient, Ban, Phased ban, Nanny state, Vaping, Second-hand smoke HealthyGamerGG's video ‘Why Your Identity Dooms You To Failure': https://www.youtube.com/watch?v=KmJmvaMIjIY Learn more about your ad choices. Visit megaphone.fm/adchoices
Changing zoning rules to allow taller and denser buildings may cause land values to go up, and public officials may try to “capture” this added value by requiring affordable units in new developments. But what happens when costs and benefits are out of balance? Seattle offers a cautionary tale.Show notes:Krimmel, J., & Wang, B. (2023). Upzoning With Strings Attached: Evidence From Seattle's Affordable Housing Mandate. Cityscape, 25(2), 257-278.City of Seattle webpage for the Mandatory Housing Affordability program.Lebret, D., Liu, C., & Valentin, M. (2024). Carrot and Stick Zoning. UEA 13th European Meeting.Manville, M., & Osman, T. (2017). Motivations for Growth Revolts: Discretion and pretext as sources of development conflict. City & Community, 16(1), 66-85.Phillips, S. (2022). Building Up the" Zoning Buffer": Using Broad Upzones to Increase Housing Capacity Without Increasing Land Values. UCLA Lewis Center for Regional Policy Studies.
In this bonus episode of Detailed, we share a LIVE conversation from the 2024 AIA Conference on Architecture & Design in Washington D.C.John Hollins III, Vice President of Sales at Cityscapes Architectural Innovations joins Cherise for this bonus episode. John highlights the diverse and customizable solutions provided by Cityscapes in everything from rooftop mechanical equipment screening and decorative laser-cut metals to canopy design, architectural signage, and more. If you enjoy this episode, visit arcat.com/podcast for more. If you're a frequent listener of Detailed, you might enjoy similar content at Gābl Media.
In the New Music Friday episode, we speak with Chicago based guitarist and songwriter Brett Ratner about his musical journey and his latest EP, Cityscapes.
In this episode of iOS Today, hosts Mikah Sargent and Rosemary Orchard dive into the second half of the 2024 Apple Design Award winners, covering the categories of Social Impact, Visuals and Graphics, and the new Spatial Computing category. They discuss standout apps and games that push the boundaries of design and functionality across Apple's platforms, including innovative uses of Apple Vision Pro technology. Social Impact category winners: Gentler Streak: A fitness app that takes a more compassionate approach to fitness tracking The Wreck: A narrative game exploring themes of grief and sisterhood Visuals and Graphics category winners: Rooms: An 8-bit style room design app with social features Lies of P: A Pinocchio-inspired action game with stunning visuals Spatial Computing category winners: djay: A DJ app that creates an immersive turntable experience in Apple Vision Pro Blackbox: A puzzle game that cleverly uses device sensors and features Shortcuts Corner: Discussion of how to add custom app icons to shortcuts in iOS 17 and 18 Rosemary and Mikah also addressed a listener question about the potential of AI-enhanced Siri to provide personalized recommendations based on user data, discussing the possibilities and limitations of such features. Hosts: Mikah Sargent and Rosemary Orchard Want access to the video version and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord. You can also contribute to iOS Today by sending an email to iOSToday@TWiT.tv.
In this episode of iOS Today, hosts Mikah Sargent and Rosemary Orchard dive into the second half of the 2024 Apple Design Award winners, covering the categories of Social Impact, Visuals and Graphics, and the new Spatial Computing category. They discuss standout apps and games that push the boundaries of design and functionality across Apple's platforms, including innovative uses of Apple Vision Pro technology. Social Impact category winners: Gentler Streak: A fitness app that takes a more compassionate approach to fitness tracking The Wreck: A narrative game exploring themes of grief and sisterhood Visuals and Graphics category winners: Rooms: An 8-bit style room design app with social features Lies of P: A Pinocchio-inspired action game with stunning visuals Spatial Computing category winners: djay: A DJ app that creates an immersive turntable experience in Apple Vision Pro Blackbox: A puzzle game that cleverly uses device sensors and features Shortcuts Corner: Discussion of how to add custom app icons to shortcuts in iOS 17 and 18 Rosemary and Mikah also addressed a listener question about the potential of AI-enhanced Siri to provide personalized recommendations based on user data, discussing the possibilities and limitations of such features. Hosts: Mikah Sargent and Rosemary Orchard Want access to the video version and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord. You can also contribute to iOS Today by sending an email to iOSToday@TWiT.tv.
In this episode of iOS Today, hosts Mikah Sargent and Rosemary Orchard dive into the second half of the 2024 Apple Design Award winners, covering the categories of Social Impact, Visuals and Graphics, and the new Spatial Computing category. They discuss standout apps and games that push the boundaries of design and functionality across Apple's platforms, including innovative uses of Apple Vision Pro technology. Social Impact category winners: Gentler Streak: A fitness app that takes a more compassionate approach to fitness tracking The Wreck: A narrative game exploring themes of grief and sisterhood Visuals and Graphics category winners: Rooms: An 8-bit style room design app with social features Lies of P: A Pinocchio-inspired action game with stunning visuals Spatial Computing category winners: djay: A DJ app that creates an immersive turntable experience in Apple Vision Pro Blackbox: A puzzle game that cleverly uses device sensors and features Shortcuts Corner: Discussion of how to add custom app icons to shortcuts in iOS 17 and 18 Rosemary and Mikah also addressed a listener question about the potential of AI-enhanced Siri to provide personalized recommendations based on user data, discussing the possibilities and limitations of such features. Hosts: Mikah Sargent and Rosemary Orchard Want access to the video version and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord. You can also contribute to iOS Today by sending an email to iOSToday@TWiT.tv.
In this episode of iOS Today, hosts Mikah Sargent and Rosemary Orchard dive into the second half of the 2024 Apple Design Award winners, covering the categories of Social Impact, Visuals and Graphics, and the new Spatial Computing category. They discuss standout apps and games that push the boundaries of design and functionality across Apple's platforms, including innovative uses of Apple Vision Pro technology. Social Impact category winners: Gentler Streak: A fitness app that takes a more compassionate approach to fitness tracking The Wreck: A narrative game exploring themes of grief and sisterhood Visuals and Graphics category winners: Rooms: An 8-bit style room design app with social features Lies of P: A Pinocchio-inspired action game with stunning visuals Spatial Computing category winners: djay: A DJ app that creates an immersive turntable experience in Apple Vision Pro Blackbox: A puzzle game that cleverly uses device sensors and features Shortcuts Corner: Discussion of how to add custom app icons to shortcuts in iOS 17 and 18 Rosemary and Mikah also addressed a listener question about the potential of AI-enhanced Siri to provide personalized recommendations based on user data, discussing the possibilities and limitations of such features. Hosts: Mikah Sargent and Rosemary Orchard Want access to the video version and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord. You can also contribute to iOS Today by sending an email to iOSToday@TWiT.tv.
In this episode of iOS Today, hosts Mikah Sargent and Rosemary Orchard dive into the second half of the 2024 Apple Design Award winners, covering the categories of Social Impact, Visuals and Graphics, and the new Spatial Computing category. They discuss standout apps and games that push the boundaries of design and functionality across Apple's platforms, including innovative uses of Apple Vision Pro technology. Social Impact category winners: Gentler Streak: A fitness app that takes a more compassionate approach to fitness tracking The Wreck: A narrative game exploring themes of grief and sisterhood Visuals and Graphics category winners: Rooms: An 8-bit style room design app with social features Lies of P: A Pinocchio-inspired action game with stunning visuals Spatial Computing category winners: djay: A DJ app that creates an immersive turntable experience in Apple Vision Pro Blackbox: A puzzle game that cleverly uses device sensors and features Shortcuts Corner: Discussion of how to add custom app icons to shortcuts in iOS 17 and 18 Rosemary and Mikah also addressed a listener question about the potential of AI-enhanced Siri to provide personalized recommendations based on user data, discussing the possibilities and limitations of such features. Hosts: Mikah Sargent and Rosemary Orchard Want access to the video version and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord. You can also contribute to iOS Today by sending an email to iOSToday@TWiT.tv.
Send us a Text Message.To learn more about Tetiana Cheprasova, please visit her page at Agency of Artists in Exile.Special thanks to Valentina Kostornichenko for acting as interpreter in this episode.Show Notes:0:00 Tetiana Cheprasova's view of the war in Ukraine & interpreter Valentina Kostornichenko1:30 Cheprasova's background and work in painting, photography, sculptures and graphic design 4:50 Giovanni Ercolani's book The Maidan Museum Preserving the Spirit of Maidan. Art, Identity and the Revolution of Dignity that features Cheprasova's paintings inspired by Caravaggio8:00 from Cheprasova's Depassement portfolio - paintings of hands, including wounded hands signifying stigmata 10:30 Mariupol woman who inspired Cheprasova20:40 ‘Stop Emotions' series of 9 paintings25:00 Cityscapes of Mariupol29:30 sculpture that's part of new work to depict destruction in Ukraine34:00 Parisian architecture35:00 consequences of war 38:00 power of art to address social injustices and the impact of war41:00 Cheprasova's view of justice 45:40 Cheprasova's work as art therapist49:20 Cheprasova's hope for viewers of her work53:00 Giovanni Ercolani's questions to Cheprasova 56:00 if only one person is impacted by your work, it's worth doing 56:50 Artists as witnesses of their timePlease share your comments and/or questions at stephanie@warfareofartandlaw.comTo hear more episodes, please visit Warfare of Art and Law podcast's website.Music by Toulme.To view rewards for supporting the podcast, please visit Warfare's Patreon page.To leave questions or comments about this or other episodes of the podcast and/or for information about joining the 2ND Saturday discussion on art, culture and justice, please message me at stephanie@warfareofartandlaw.com. Thanks so much for listening!© Stephanie Drawdy [2024]
Kyle shares his thoughts on the fifth issue of The Question by Dennis O'Neil and Denys Cowan The video essay Kyle did on this issue can be found here --- Send in a voice message: https://podcasters.spotify.com/pod/show/kyle-scher/message Support this podcast: https://podcasters.spotify.com/pod/show/kyle-scher/support
Fluent Fiction - French: Art and Friendship Unite at Café des Deux Moulins Find the full episode transcript, vocabulary words, and more:fluentfiction.org/art-and-friendship-unite-at-cafe-des-deux-moulins Story Transcript:Fr: Sous le ciel bleu de Paris, il y a un petit café nommé le Café des Deux Moulins.En: Under the blue sky of Paris, there is a small café named the Café des Deux Moulins.Fr: Ce café est célèbre dans le quartier.En: This café is well-known in the neighborhood.Fr: Aujourd'hui, c'est un jour spécial pour Luc, Élise et Margaux.En: Today is a special day for Luc, Élise, and Margaux.Fr: Luc est un jeune artiste.En: Luc is a young artist.Fr: Il aime peindre des scènes de la ville.En: He loves painting scenes of the city.Fr: Élise est la gérante du café.En: Élise is the manager of the café.Fr: Elle connait bien Luc et apprécie ses tableaux.En: She knows Luc well and appreciates his paintings.Fr: Margaux est une amie de Luc.En: Margaux is a friend of Luc.Fr: Elle est photographe.En: She is a photographer.Fr: Ensemble, ils préparent une exposition d'art au café.En: Together, they are preparing an art exhibition at the café.Fr: Le matin est calme.En: The morning is calm.Fr: Les trois amis arrivent tôt au café.En: The three friends arrive early at the café.Fr: Luc apporte ses peintures.En: Luc brings his paintings.Fr: Élise prépare les tables et les chaises.En: Élise arranges the tables and chairs.Fr: Margaux vérifie ses photos et affiche les meilleures sur les murs.En: Margaux checks her photos and displays the best ones on the walls.Fr: "Regarde cette peinture," dit Luc à Élise.En: "Look at this painting," Luc says to Élise.Fr: "C'est le pont Alexandre III.En: "It's the Pont Alexandre III.Fr: Tu aimes?"En: Do you like it?"Fr: "Oui, c'est magnifique!"En: "Yes, it's beautiful!"Fr: répond Élise avec un sourire.En: replies Élise with a smile.Fr: "Ce sera parfait ici."En: "It will be perfect here."Fr: Margaux accroche une photo de la Tour Eiffel.En: Margaux hangs a photo of the Eiffel Tower.Fr: "Cette photo est spéciale pour moi," dit-elle.En: "This photo is special to me," she says.Fr: "Je l'ai prise un soir d'été.En: "I took it one summer evening.Fr: La lumière était parfaite."En: The light was perfect."Fr: Les clients commencent à arriver.En: Customers start to arrive.Fr: Ils regardent les œuvres d'art.En: They look at the artworks.Fr: Ils sont impressionnés.En: They are impressed.Fr: Une vieille dame s'arrête devant une peinture de Luc.En: An old lady stops in front of one of Luc's paintings.Fr: "C'est merveilleux," dit-elle.En: "It's wonderful," she says.Fr: "Je reconnais cette rue!"En: "I recognize this street!"Fr: Luc est heureux.En: Luc is happy.Fr: Élise sert des cafés et des croissants aux clients.En: Élise serves coffee and croissants to the customers.Fr: Margaux prend des photos de l'événement.En: Margaux takes pictures of the event.Fr: L'ambiance est joyeuse et conviviale.En: The atmosphere is joyful and friendly.Fr: Un jeune homme s'approche de Margaux.En: A young man approaches Margaux.Fr: "J'adore cette photo de Notre-Dame," dit-il.En: "I love this photo of Notre-Dame," he says.Fr: "Je voudrais l'acheter.En: "I would like to buy it.Fr: Est-elle à vendre?"En: Is it for sale?"Fr: "Oui, elle est à vendre," répond Margaux.En: "Yes, it is for sale," replies Margaux.Fr: "Merci beaucoup!"En: "Thank you very much!"Fr: Le jeune homme achète la photo.En: The young man buys the photo.Fr: Luc vend aussi deux de ses peintures.En: Luc also sells two of his paintings.Fr: Élise est contente de voir son café rempli de vie et de culture.En: Élise is pleased to see her café filled with life and culture.Fr: À la fin de la journée, les trois amis sont fatigués mais heureux.En: At the end of the day, the three friends are tired but happy.Fr: "C'était une belle journée," dit Luc.En: "It was a beautiful day," says Luc.Fr: "Merci à vous deux."En: "Thank you both."Fr: "Oui, merci Élise pour ton aide," dit Margaux.En: "Yes, thank you Élise for your help," says Margaux.Fr: "Et merci Luc pour tes merveilleuses peintures."En: "And thank you Luc for your wonderful paintings."Fr: Le soleil se couche sur Paris.En: The sun sets over Paris.Fr: Le Café des Deux Moulins est calme à nouveau.En: The Café des Deux Moulins is calm again.Fr: Mais il y a une chaleur dans l'air, le signe d'une belle amitié et d'une journée réussie.En: But there is warmth in the air, a sign of a beautiful friendship and a successful day.Fr: Luc, Élise et Margaux sont satisfaits.En: Luc, Élise, and Margaux are satisfied.Fr: Ils ont partagé leur passion avec le monde.En: They have shared their passion with the world.Fr: Et ils savent qu'ils recommenceront bientôt.En: And they know they will do it again soon.Fr: L'art et l'amitié continuent de briller dans le cœur de Paris.En: Art and friendship continue to shine in the heart of Paris. Vocabulary Words:painter: peintremanager: gérantephotographer: photographeexhibition: expositioncalm: calmearranges: préparedisplays: affichepainting: peinturebeautiful: magnifiquesmile: sourirehangs: accrocherecognize: reconnaisjoyful: joyeusefriendly: convivialeapproaches: s'approchebuys: achètesells: vendpleased: contentefilled: remplitired: fatiguéswonderful: merveilleusessets: se couchewarmth: chaleursign: signesharing: partagerpassion: passionshine: brillerheart: cœursun: soleilcustomers: clients
Tauranga's gets a vibrant makeover with Roof Painters Tauranga at the helm! Witness the magic unfold as the city's premier commercial painters weave their expertise to elevate urban aesthetics. Ready to redefine your space? Dial 028 417 0142 or hop on over to RoofPaintingTauranga.nz/contact now! Roof Painters Tauranga City: Tauranga South Address: 640 Cameron Road Website: https://roofpaintingtauranga.nz Phone: +64284170142 Email: roofpainterstauranga1@gmail.com
Elevate Tauranga's Skyline! Expert Commercial Painters at Your Service! From Roofs to Walls, We've Got You Covered! Transform Your Property Today! Visit roofpaintingtauranga.nz/contact or Call 028 417 0142. Roof Painters Tauranga City: Tauranga South Address: 640 Cameron Road Website: https://roofpaintingtauranga.nz Phone: +64284170142 Email: roofpainterstauranga1@gmail.com
Fluent Fiction - Dutch: Lost in Amsterdam: Finding Home Among Tulips and Towers Find the full episode transcript, vocabulary words, and more:fluentfiction.org/lost-in-amsterdam-finding-home-among-tulips-and-towers Story Transcript:Nl: Fietswielen zoeven over het pad.En: Bicycle wheels zoom over the path.Nl: Maarten houdt van fietsen.En: Maarten loves cycling.Nl: Hij vindt het leuk om door de straten van Amsterdam te rijden.En: He enjoys riding through the streets of Amsterdam.Nl: De zon schijnt en de huizen zijn mooi.En: The sun is shining and the houses are beautiful.Nl: De grachten zijn als blauwe linten tussen de oude huizen.En: The canals are like blue ribbons between the old houses.Nl: Maar vandaag is anders.En: But today is different.Nl: Maarten is verdwaald.En: Maarten is lost.Nl: De paden zijn vreemd.En: The paths are unfamiliar.Nl: De huizen zijn niet bekend.En: The houses are not recognizable.Nl: Maarten is in de war.En: Maarten is confused.Nl: De grachten schitteren niet meer zo vrolijk.En: The canals no longer sparkle so cheerfully.Nl: Maarten stopt om rond te kijken.En: Maarten stops to look around.Nl: Waar is hij?En: Where is he?Nl: Hij ziet alleen een groot veld.En: He sees only a large field.Nl: En knip, knap, knip: het veld is vol met tulpen.En: And clip, clop, clip: the field is full of tulips.Nl: Rode, gele, roze - zoveel kleuren.En: Red, yellow, pink - so many colors.Nl: Het tulpenveld is als een kleurenfeest.En: The tulip field is like a colorful festival.Nl: Maar Maarten is niet blij.En: But Maarten is not happy.Nl: Hij is bang.En: He is scared.Nl: Hoe komt hij thuis?En: How will he get home?Nl: Maarten begint te fietsen.En: Maarten starts cycling.Nl: Hij rijdt langzaam.En: He rides slowly.Nl: Hij probeert de weg te vinden.En: He tries to find his way.Nl: Hij ziet een oude molen.En: He sees an old windmill.Nl: Is die molen bij hem thuis?En: Is that windmill near his home?Nl: Nee, dat is het niet.En: No, it is not.Nl: Hij ziet een brug.En: He sees a bridge.Nl: Is die brug bij hem thuis?En: Is that bridge near his home?Nl: Nee, dat is het ook niet.En: No, that's not it either.Nl: Maarten wordt steeds banger.En: Maarten becomes increasingly scared.Nl: Maar dan ziet hij iets.En: But then he sees something.Nl: Hij ziet hoge torens.En: He sees tall towers.Nl: Zijn dat de torens van zijn stad?En: Are those the towers of his city?Nl: Ja, dat zijn ze!En: Yes, they are!Nl: Maarten begint te lachen.En: Maarten begins to laugh.Nl: Hij fietst snel naar de torens.En: He cycles quickly towards the towers.Nl: De wind waait door zijn haren.En: The wind blows through his hair.Nl: De tulpenveld lijkt een kleurrijk tapijt achter hem.En: The tulip field looks like a colorful carpet behind him.Nl: Maarten bereikt eindelijk Amsterdam.En: Maarten finally reaches Amsterdam.Nl: Hij herkent de straten.En: He recognizes the streets.Nl: Hij herkent de grachten.En: He recognizes the canals.Nl: De stad is als een oude vriend.En: The city is like an old friend.Nl: Maarten is niet langer bang.En: Maarten is no longer afraid.Nl: Hij is weer thuis.En: He is back home.Nl: De wielen van Maarten zoeven weer over het pad.En: Maarten's wheels zoom over the path again.Nl: Hij houdt van fietsen.En: He loves cycling.Nl: En zelfs als hij weer verdwaalt, zal hij de weg naar huis vinden.En: And even if he gets lost again, he will find his way home.Nl: Want thuis is daar waar het hart is, zelfs als dat betekent fietsen door een veld vol tulpen.En: Because home is where the heart is, even if it means cycling through a field of tulips. Vocabulary Words:en: nlbicycle: fietswheels: wielenzoom: zoevenpath: padMaarten: Maartenloves: houdt vancycling: fietsenenjoys: vindt het leukriding: rijdenstreets: stratenAmsterdam: Amsterdamsun: zonshining: schijnthouses: huizenbeautiful: mooicanals: grachtenblue: blauweribbons: lintenold: oudeBut: Maartoday: vandaagdifferent: anderslost: verdwaaldpaths: padenunfamiliar: vreemdrecognizable: bekendconfused: in de warsparkle: schitteren
Fluent Fiction - Hungarian: Twists and Turns: A Budapest Bathhouse Friendship Challenge Find the full episode transcript, vocabulary words, and more:fluentfiction.org/twists-and-turns-a-budapest-bathhouse-friendship-challenge Story Transcript:Hu: Budapest, melynek szívében Anna és István, két jó barát élvezte szombat délutánjukat. A Gellért Fürdőben találkoztak, egymás társaságának és a gyönyörű termálfürdő lágy pataklásának élvezete miatt. De bonyolódott a dolog, amikor a fürdőben lévő labirintusszerű építészet elkapta őket.En: Budapest, in the heart of which Anna and István, two good friends, enjoyed their Saturday afternoon. They met at the Gellért Baths, enjoying each other's company and the soothing flow of the beautiful thermal baths. The situation became more complicated when the labyrinthine architecture of the baths captured them.Hu: Anna és István kitalálta, hogy játszanak egy játékot: ki találja meg a legrövidebb idő alatt a kiutat a fürdőből. Nagyjából mosolyogva váltattak meg, hogy végül eltűntek egymás látóteréből. Az idő akkor szállt, amikor mindketten vadvízi csúszdákban és pezsgőfürdőkben találták magukat. Valahogy mégis mindketten elvesztek a komplex labirintusban. Mindannyian zavarodottak voltak, képesek voltak a logikájukra és az emlékezetükre támaszkodni ahhoz, hogy megtalálják az útjukat kifelé.En: Anna and István came up with a game: to see who could find the way out of the baths in the shortest time. With smiles on their faces, they quickly separated, disappearing from each other's view. Time flew by as they found themselves in wild water slides and bubbly pools. Yet, they both ended up getting lost in the complex maze. Confused, they relied on their logic and memories to find their way out.Hu: A nap véget ért, és a napló szélén állva követték az alkony színekben úszó termálmedencét. István megnézte az óráját, az barátja még mindig hiányzott. Aggódni kezdett Annáért. Megpróbált néhány személyzeti tagot értesíteni, de senki sem tudott segíteni. Megszilárdította elhatározását, hogy inkább egyedül keresi meg Annát.En: As the day came to an end, standing by the edge of the pool, they followed the twilight colors dancing on the thermal pool. István checked his watch, his friend was still missing. Worried for Anna, he tried to inform some staff members, but no one could help. He made a firm decision to search for Anna on his own.Hu: Másfelől, a távolban, Anna volt. Fáradtan és csalódottan ült a beltéri medence szélén, azon gondolkodott, hogyan került erre a helyre. A fürdő által felkínált kényelem ellenére folyamatosan érezte az aggodalmat és a félelmet. Hiányzott a barátja; István.En: On the other side, in the distance, was Anna. Exhausted and disappointed, she sat by the indoor pool, wondering how she ended up there. Despite the comfort offered by the baths, she still felt worry and fear. She missed her friend, István.Hu: Hosszú percek teltek el. Végül István felfedezett egy keskeny járatot, amely egy központi medence felé vezetett. Egyedül tartózkodó lányt pillantott meg, aki a medence szélén ült, ami csak Anna lehetett. A siker és a megkönnyebbülés boldogságos mosolyt csalt arcára.En: Minutes turned into long moments. Finally, István discovered a narrow passage leading to a central pool. He spotted a girl sitting alone by the pool, who could only be Anna. Success and relief brought a happy smile to his face.Hu: Anna szinte felugrott a meglepetéstől és az örömtől, amikor meglátta Istvánt. Boldogan sietett felé, és elmondta neki, mennyire hiányzott. Az öröm és a könnyek keveréke tükröződött az arcán.En: Almost jumping with surprise and joy, Anna saw István. Happily, she rushed towards him, expressing how much she missed him. The mix of joy and tears reflected on her face.Hu: A nap után István és Anna együtt találtak kiutat a labirintusból, kéz a kézben, valóban megtapasztalva a szorongás érzését, ami összekötötte őket. A félelem, a fáradtság és az öröm olyan élmény volt, amit soha nem felejtenek el.En: After the day, István and Anna found their way out of the labyrinth together, hand in hand, truly experiencing the anxiety that bound them. The fear, fatigue, and joy created an unforgettable experience.Hu: Ezzel a tapasztalattal elhatározták, hogy többet nem játszanak többé hozzá hasonló játékot. De azt is megjegyezték, hogy az események mélyebben összekötöttek őket, mint bármi más korábban. Eközben Budapest, a gyönyörű város, csendesen, de büszkén állt ott, mintha figyelne és tanúsítaná ezt a kis kalandot.En: With this shared experience, they decided never to play such a game again. They also noted how the events had connected them on a deeper level than ever before. Meanwhile, Budapest, the beautiful city, stood quietly and proudly, as if observing and acknowledging this little adventure. Vocabulary Words:Budapest: BudapestAnna: AnnaIstván: Istvángood friends: jó barátSaturday: szombatafternoon: délutánGellért Baths: Gellért Fürdőenjoying: élvezvecompany: társaságsoothing: lágyflow: pataklásbeautiful: gyönyörűthermal baths: termálfürdősituation: helyzetcomplicated: bonyolultlabyrinthine: labirintusszerűarchitecture: építészetcapture: elkapgame: játékway out: kiútshortest time: legrövidebb idősmiles: mosolyokwild: vadwater slides: vadvízi csúszdákbubbly pools: pezsgőfürdőkconfused: zavarodottlogic: logikamemories: emlékekfind: megtalálniend: vége
Ferran Kefauver is from Cityscape is in the studio to talk about Taste Of The Town and the membership drive.
Fluent Fiction - Japanese: Yuki's Journey: Navigating Tokyo Station's Cityscape Chaos Find the full episode transcript, vocabulary words, and more:fluentfiction.org/yukis-journey-navigating-tokyo-stations-cityscape-chaos Story Transcript:Ja: 東京のスカイラインは、まるでビルの洪水がサンセットに輝く海に注ぎ込んでいるかのように見えた。その美しさに見とれていた中にいたのは、小さな女の子、ゆきだった。彼女が迷いに迷って、サイハテまで来てしまった場所、それは東京駅だ。En: The skyline of Tokyo appeared as though a flood of buildings was pouring into the sea shimmering with the sunset. Among those mesmerized by its beauty was a little girl named Yuki. Lost in her thoughts, she found herself at the faraway destination of Tokyo Station.Ja: ラッシュアワー。駅は人の波で溢れていた。向かいから来る流れ、後ろから押す流れ、足を運ぶ全ては一つの方向へと向かい、その逆に立っているゆきは途方に暮れていた。En: It was rush hour. The station was overflowing with waves of people. Streams coming from opposite directions, pushing from behind, every footstep moving in one direction, while Yuki, standing against the flow, was at a loss.Ja: ゆきは自宅からはるか遠くにいた。居場所なんて確かなものではなく、彼女の心の中はいますぐ家に帰りたいという思いで満ちていた。でも、流れる人々は彼女の願いを無視して、川のように勢いよく流れていく。En: Yuki was far from her home. Her place of belonging was uncertain, and her heart was filled with the immediate desire to return home. But the flowing crowd disregarded her wish, swiftly carrying on like a river.Ja: だけど、ゆきはあきらめなかった。彼女の小さな体はその川に押し流されそうになりながらも、逆流する勇気を続けていた。その眼差しは伊達に前方を見据えていた。おうちへ帰る方法探しの旅は続いた。En: However, Yuki did not give up. Despite her small frame being almost swept away by the river, she continued to bravely swim against the current. Her gaze was fixed ahead, determined to find a way back home.Ja: 彼女はスマートフォンを取り出し、頼りにすることにした。ゆきが指先に力を込めて画面を操作すると、地図が広がり、帰路が見えてきた。それは、ゆきにとって新たな希望の光だった。そして、この光は予想以上に明るかった。En: She took out her smartphone as a last resort. With determination in her fingertips, she operated the screen, the map expanded, and the way back home became clear. It was a new ray of hope for Yuki. And this light was brighter than expected.Ja: 彼女はその指示通りに移動を始め、周囲の混雑が軽減するにつれて、帰り道がスムーズになっていった。誰にも気づかれず、ゆきはその場からゆっくりと動き出し、人の波から離れた。En: Following the instructions, she began to move, and as the surrounding crowd eased, her journey back home became smoother. Unnoticed by anyone, Yuki slowly moved away from the crowd.Ja: 家路についていくゆきの足元は明らかに軽くなって、人混みでも自分だけが進める方向に向かっていると確信が芽生えてきた。最終的に、彼女は自分の家までの道のりを見つけた。En: With each step toward home, Yuki felt lighter, and she was confident that she alone was moving in the right direction in the crowd. Eventually, she found her way back home.Ja: 彼女の冒険は終わり、ゆきは家に帰って安堵の息をついた。混雑した駅から抜け出し、失った道を見つけ出すという事は、ゆきにとって勇気と知恵、堅実さが求められた試練だったのだ。しかしそれを乗り越えた彼女は、もう二度と迷うことはないと、自身の力を確信した。En: Her adventure came to an end, and Yuki heaved a sigh of relief upon reaching home. Escaping the crowded station and finding the lost path was a test that required courage, wisdom, and resourcefulness from Yuki. Overcoming it, she was confident in her own strength and was certain she would never get lost again.Ja: 東京の夜景が彼女の窓から見える。彼女の中には大きな都市の迷路でも、行き場を失うことはない自信が芽生えていた。それはゆき自身が成長し、それを乗り越えた証だと、彼女は胸を張って誇りに思ったのだ。En: From her window, Yuki could see the Tokyo night view. Despite the intricate maze of the big city, she was confident she would never lose her way. It was a testament to her growth and the pride she felt in overcoming it. Vocabulary Words:flood: 洪水buildings: ビルsea: 海sunset: サンセットmesmerized: 魅了されたdestination: 目的地rush hour: ラッシュアワーwaves: 波streams: 流れopposite: 向かいdirections: 方向uncertain: 不確かdesire: 望みcrowd: 人々swiftly: 素早くbravely: 勇敢にgaze: 視線expanded: 拡大したinstructions: 指示eased: 和らいだjourney: 旅unnoticed: 気づかれないconfident: 自信があるescaping: 脱出するtest: 試練resourcefulness: 知恵maze: 迷路growth: 成長
Fluent Fiction - Dutch: The Rainy Ride Home: Cycling Adventures in Amsterdam Find the full episode transcript, vocabulary words, and more:fluentfiction.org/the-rainy-ride-home-cycling-adventures-in-amsterdam Story Transcript:Nl: Het regende heel hard in Amsterdam.En: It was raining very hard in Amsterdam.Nl: Femke stond onder een brug.En: Femke was standing under a bridge.Nl: Ze moest naar huis, maar vond het niet leuk om nat te worden.En: She needed to go home, but she didn't like getting wet.Nl: Ze had een fiets en een paraplu.En: She had a bike and an umbrella.Nl: Maar ze had nooit eerder gefietst met een paraplu.En: But she had never cycled with an umbrella before.Nl: Femke dacht na.En: Femke thought.Nl: De druppels tikten op haar paraplu.En: The raindrops were tapping on her umbrella.Nl: De straten van Amsterdam waren nat en glinsterend.En: The streets of Amsterdam were wet and glistening.Nl: Ze wilde naar huis.En: She wanted to go home.Nl: Daar was het warm en droog.En: It was warm and dry there.Nl: Ze hield de paraplu in haar hand.En: She held the umbrella in her hand.Nl: Ze stapte op haar fiets.En: She got on her bike.Nl: Ze zette een voet op de trapper en ging vooruit.En: She put a foot on the pedal and moved forward.Nl: Het was moeilijk.En: It was difficult.Nl: De wind blies tegen de paraplu.En: The wind was blowing against the umbrella.Nl: Het stuur wilde niet rechtdoor.En: The handlebars wouldn't stay straight.Nl: Ze fietste langzaam over de brug.En: She cycled slowly over the bridge.Nl: De grachten van Amsterdam waren donker en diep.En: The canals of Amsterdam were dark and deep.Nl: Ze zag huizen met grote ramen en lichten aan.En: She saw houses with large windows and lights on.Nl: Ze zag eenden die in de regen zwommen.En: She saw ducks swimming in the rain.Nl: Ze werd nat, maar de paraplu hield haar een beetje droog.En: She got wet, but the umbrella kept her somewhat dry.Nl: Er was veel wind in de stad.En: There was a lot of wind in the city.Nl: De straat was nat.En: The street was wet.Nl: Femke viel bijna, maar ze viel niet.En: Femke almost fell, but she didn't.Nl: Ze hield de paraplu stevig vast.En: She held the umbrella tightly.Nl: Ze fietste door.En: She kept cycling.Nl: Ze fietste door smalle straatjes.En: She cycled through narrow streets.Nl: Ze fietste langs winkels die gesloten waren.En: She cycled past closed shops.Nl: Ze fietste langs de bakker, de slager en de kaaswinkel.En: She cycled past the bakery, the butcher, and the cheese shop.Nl: Niemand was buiten.En: No one was outside.Nl: Iedereen was binnen waar het warm was.En: Everyone was inside where it was warm.Nl: Ze kwam thuis.En: She got home.Nl: Ze zette haar fiets tegen de muur.En: She leaned her bike against the wall.Nl: Ze deed haar jas uit en hing haar natte paraplu op.En: She took off her coat and hung her wet umbrella.Nl: Femke was blij dat ze thuis was.En: Femke was happy to be home.Nl: Ze was nat, maar ze was ook trots.En: She was wet, but she was also proud.Nl: Ze had gefietst in de regen, met een paraplu.En: She had cycled in the rain, with an umbrella.Nl: Vanaf die dag was Femke niet meer bang voor de regen.En: From that day on, Femke wasn't afraid of the rain anymore.Nl: Ze wist dat ze kon fietsen, zelfs met een paraplu.En: She knew she could cycle, even with an umbrella.Nl: Ze wist dat Amsterdam mooi was in de regen.En: She knew Amsterdam was beautiful in the rain.Nl: En ze wist dat thuis warm en droog was, na een lange fietstocht door de regen.En: And she knew home was warm and dry, after a long bike ride through the rain. Vocabulary Words:rain: regenhard: hardAmsterdam: AmsterdamFemke: Femkebridge: brughome: huiswet: natbike: fietsumbrella: paraplucycle: fietsenthought: dachtraindrops: druppelsstreets: stratenglistening: glinsterendwarm: warmdry: drooghand: handfoot: voetpedal: trapperdifficult: moeilijkwind: windblowing: bliescanals: grachtendark: donkerdeep: diephouses: huizenwindows: ramenlights: lichtenducks: eendenswimming: zwommen
The African continent is projected to have the fastest urban growth rate in the world: by 2050, Africa's cities will be home to an additional 950 million people. While this surge presents urban centers with a wealth of opportunities such as a larger workforce, increased consumer markets, and greater potential for cultural exchange, it also brings forth substantial challenges. The rapid population growth can exacerbate existing problems such as inadequate infrastructure, housing shortages, and environmental concerns. African cities with their unique history and socio-economic landscape, must navigate these complexities while harnessing the potential for innovation and economic diversification that a growing populace brings. Obvious Katsaura is a senior lecturer in sociology at the University of the Witwatersrand. His research interests are in, and at the intersections of, the fields of transnational urbanism, transnational religiosity, religious urbanism, urban politics and urban violence. Key highlightsIntroduction – 00:24The development impacts of urban inequality – 03:36Fear, insecurity, and fortress mentality – 10:58Migrant life in Johannesburg – 15:38The role of churches in providing security and hope – 21:18Pentecostalism and development in Lagos – 30:38 HostProfessor Dan Banik (@danbanik @GlobalDevPod)Apple Google Spotify YouTubeSubscribe: https://globaldevpod.substack.com/
Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player. Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium
Jubel, Trubel, Heiterkeit - heute, am 01. Oktober erscheint die 400. Episode von "XtraChill"! Für den lieben Andreas ein Grund, ein wenig stolz zu sein, denn knapp sechzehneinhalb Jahren auf Sendung stehen im schnelllebigen Zeitgefüge des Internet für ein ganzes Zeitalter! Viele "runde" dreistellige Episoden waren in der Vergangenheit nicht selten ganz besondere Ausgaben; so widmeten Jürgen und Andreas vor ziemlich genau dreizehn Jahren die 100. Folge dem Projekt "Fonogeri" und seiner grandiosen "Roughneck Selection". Auftragswerke gab es seit dem immer wieder, die bislang letzte monographische Sonderausgabe war Episode 351, in der "Dott. Santafeo" einen ganz exklusiven Mix seiner Werke präsentiete. Und genau das erwartet Euch Hörer heute auch, denn das kroatische Soloprojekt "NuLix" hat sich spontan bereit erklärt, für diese Sonderfolge kreativ zu werden. Das Ergebnis ist ein durchgehender Mix mit dem Titel "Cityscape"; eine Melange aus diversen Eigenkompositionen, die teilweise auch mit dem Projekt "Expozed" entstanden sind, und die nun ganz exklusiv nur hier bei "XtraChill" zu erleben ist. Dabei steigert sich das Werk von Ambientsounds und Soundscapes zu jazzig angehauchten Momenten - Robert präsentiert seine ganze musikalische Bandbreite. Viel Spaß mit diesem erlebnisreichen Experiment! Hip Hip Hooray! Today, on October 1st, the 400th episode of "XtraChill" is released! A reason for dear Andreas to be a little proud, because almost sixteen and a half years on air represents an entire era in the fast-moving time structure of the Internet! In the past, many important three-digit episodes were often very special editions; almost exactly thirteen years ago, Jürgen and Andreas dedicated the 100th episode to “Fonogeri” and its magnificent “Roughneck Selection”. Since then, there have been a number of commissioned works; the last monographic special edition to date was episode #351, in which "Dott. Santafeo" presented a very exclusive mix of his works. And that's exactly what listeners can expect today, because the croatian solo project "NuLix" has spontaneously agreed to get creative for this special episode. The result is a continuous mix titled “Cityscape”; a melange of various original compositions, some of which were created with the project “Expozed”, and which can now only be experienced exclusively here at “XtraChill”. The work increases from ambient sounds and soundscapes to jazzy moments - Robert presents his entire musical range. Have fun with this exciting experiment!
Dr. Luis Mata of the University of Melbourne Australia details how the installation of just 12 native plant species turned a small urban greenspace almost overnight into a hotspot for native insect biodiversity
My guest this week is Blanche Cameron, who leads UCL Bartlett School of Architecture's Environmental Design and Greening Cities modules, and is an urban green infrastructure advocate who works closely with industry and the government on urban greening issues. To say our towns and cities are not always good examples of environmentally sound design and biodiversity would be quite the understatement, but Blanche is one of a group of outspoken advocates for nature inclusive design who are are working towards better outcomes in this regard. Dr Ian Bedford's Bug of the Week: Dagger flies What We Talk About The built environment and biodiversity collapse Landscaping in towns and cities How good design can help mitigate biodiversity loss and climate change Vertical planting and green roofs Do we need a coherent plan or is it up to individuals to start changing their landscapes? “Productising” and the construction industry's need for homogeneity Where does technologically fit in? About Blanche Cameron Blanche leads UCL Bartlett School of Architecture's Environmental Design and Greening Cities modules, and is a tutor on the Making Cities module and Environmental Design modules in the Landscape Architecture Masters courses. She is currently coordinating the Living Landscape Strategy for UCL's £1Bn UCL East development, and sits on UCL's campus greening ‘Wild Bloomsbury' steering group. Blanche is an urban green infrastructure advocate, working closely with industry and government, and especially with the independent advisory organisation Livingroofs.org founded by Dusty Gedge in 2004. She edited the 2019 policy update report on the impact of 10 years of urban greening through the London Plan Green Roofs and Walls 2008 policy by Dusty Gedge and Gary Grant. Links Blanche on LinkedIn www.naturalgrower.co.uk www.veteransgrowth.org Other episodes if you liked this one: John Little Green Roofs with Dr Anna Zakrisson Patreon
This week Wes and Todd sit down with Colorado Springs Artist, Clay Ross. Clay discusses growing up in Colorado Springs, his journey as an Artist, being color blind, the “ache” to make art, working in acrylic, his two series, being a cheerleader for his community, True North Art Gallery, mixed media, abstract work, cityscapes, his current exhibition, Colorado Springs pride, light, pricing, selling art, Yobel, and The Look Up Gallery. Check out Clay's work at his website www.clayross.artClay's exhibition “City Series” opens Friday, August 4th at The Look Up Gallery inside Yobel.Yobel and The Lookup Gallery are located at:11 E. Bijou StreetColorado Springs, CO 80903 Follow Clay on social media:Instagram - www.instagram.com/719clay/@719clayFacebook - www.facebook.com/719clay You can check out The Look Up Gallery at www.thelookupgallery.comFollow The Look Up Gallery on social media:Instagram - www.instagram.com/thelookupgallery/@thelookupgallery Facebook - www.facebook.com/thelookupgallery Check out Clay & Emily's fair trade, ethically sourced boutique, Yobel, via the website www.shopyobel.comFollow Yobel on social media:Instagram – www.instagram.com/shopyobel/@shopyobelFacebook - www.facebook.com/shopyobel
The pastry shop Sweet Greek in Spring made it to Yelp's list of 'Favorite Mom & Pop Businesses'....and a Houston artist has been capturing our amazing cityscapes for decades
How CityScapes Grew to Become an Industry Leader in Innovative Architectural ProductsAdam McCool, VP of marketing and sales for CityScapes Architectural Innovations, has a track record of success in the fields of sales, marketing, and product development. Since joining CityScapes Architectural Solutions, he continues to lead initiatives that have driven top-line growth and innovation. With more than two decades of experience in the building products sector, he has created sales and marketing programs and has worked with a wide range of companies, from family-owned businesses to multibillion-dollar corporations. Adam holds a Master's degree in Business Strategy from The Ohio State University.This week on EntreArchitect podcast, How CityScapes Grew to Become an Industry Leader in Innovative Architectural Products with Adam McCool.Learn more about Adam at CityScapes, and connect with him on LinkedIn.
Join Kosta and his guest: Melinda Keifer, Economic Development Coordinator, Community Development Liaison and Former Founding Executive Director of CityScape. Melissa has represented the Upper Cumberland across the state of Tennessee advocating for growth, expansion and the betterment of Middle Tennessee. Better Together with Kosta Yepifantsev is recorded in Cookeville, TN.Find out more about CityScape: https://cookevillecityscape.com/Find out more about Cookeville Chamber of Commerce and Economic Development: https://cookevillechamber.com/Find out more about Kosta Yepifantsev:http://kostayepifantsev.com/
Where do you live? Who are your neighbors? Do you rent or own? What housing is available in your community? Today's episode of stats and stories focuses on how and why we want to understand Americans' experience with housing, with guest Dr. Emily Molfino. Dr. Emily Molfino is the Special Assistant to the Chief Scientist at the U.S. Census Bureau. Her work focuses on improving data dissemination and the use of administrative data for the Census. While previously at the Census, Dr. Molfino worked extensively on modernizing the American Housing Survey using administrative data and process improvements. During this time, Dr. Molfino also produced research on the use of housing administrative data, which was published in Cityscape during her work at HUD.
Drs. Diwakar Davar and Jason Luke discuss KEYNOTE-716, KEYNOTE-942, RELATIVITY-047, and other key advances in melanoma, including the promise of mRNA vaccines in melanoma and potentially other cancers, as well exciting advances in neoadjuvant therapies across malignancies featured at the 2023 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello, and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh Hillman Cancer Center. I'm delighted to have my colleague and good friend Dr. Jason Luke on the podcast today to discuss some practice-changing studies and other advances in immunotherapy that were featured at the 2023 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the director of the Cancer Immunotherapy Center, as well as the associate director of clinical research at the University of Pittsburgh's Hillman Cancer Center. You can find both of our disclosures in the transcript of this episode, and disclosures of all guests on the ASCO Daily News Podcast are available on our transcripts at asco.org/DNpod. Jason, there was a lot of exciting data in the immunotherapy space highlighted at the Annual Meeting, and it's great to have you back on the podcast to discuss some of this work. Dr. Jason Luke: Thanks for having me. Dr. Diwakar Davar: So, the abstracts that we had selected have several key themes. We'll be covering some of the early advances in melanoma in the stage 2 and stage 2B/C space with KEYNOTE-716. I think this is a study that you know a little bit about seeing you are the presenting author and the principal investigator for the study, as well as the pivotal KEYNOTE-942 trial. And then going on to themes with using third-generation checkpoints, neoadjuvant therapy in non-small-cell lung cancer, and cutaneous squamous cell carcinoma. But we'll start with KEYNOTE-716. So, this is LBA9505, the study which evaluated pembrolizumab versus placebo as adjuvant therapy in stage 2B and stage 2C melanoma patient population for which historically there was no real effective therapy other than remotely interferon. And these are the final results of the DMFS analysis from this phase 3 trial. So, Jason, what are your thoughts about this, and can you contextualize the results relative to the recent publication? Dr. Jason Luke: Thanks. I think the important point to level set on this was just a few years ago; this was a population of patients that we didn't treat in clinic. In fact, sometimes they weren't even referred to medical oncology for evaluation. And that was despite the fact that we knew from historical data that the risk of melanoma-specific survival, death from melanoma, was just as high for this population of patients as it was for the patients with stage 3 melanoma, where obviously adjuvant immunotherapy has been a standard for quite some time. And so we launched this clinical trial, KEYNOTE-716. It was a global, randomized phase 3 study of almost 1,000 patients, randomizing patients to either get pembrolizumab or placebo. Importantly, these patients being those with deep primary lesions, stage 2B and 2C with negative sentinel lymph node evaluation. People will recall that this study hit its primary endpoint on the first protocol-specified analysis at a year. And what we updated at ASCO this year was the final analysis of distant metastasis-free survival. Obviously, an important secondary endpoint because if patients eventually going to develop metastatic disease and pass away, it's the distant metastasis that we worry about. And what we saw in this trial with a landmark 36-month follow-up median of 39 months was that the benefit was increasing. In other words, the magnitude of the hazard ratio change was increasing over time as would be expected, such that at this analysis there was a 41% reduction in the risk of distant metastasis for patients treated with pembrolizumab versus placebo. And we saw a consistent benefit in the recurrence-free survival also out through that same period of time and importantly no change in the safety summary with of course the adverse event profile of pembrolizumab being what it is and well understood across oncology. So I think these are very important data because they really kind of set the stage for the field. It is now the case that at least discussing adjuvant therapy for patients with stage 2B and 2C is the standard of care; it should be offered to all the patients. Of course, it's always a risk-benefit about whether or not patients want to pursue adjuvant therapy versus consideration of treatment at the time of recurrence. But in my clinic at least, many patients do prefer to try to eliminate the possibility of recurrence and distant metastasis as much as possible. So I think these are very important data because they really level set the field for what to expect in this population of patients and then they also start to set the table for what's going to come after this. And that's going to be sort of the next step in our conversation here because the next generation of adjuvant studies in melanoma are now going to think about all of melanoma in the adjuvant setting as really one entity, starting from stage 2B going all the way through stage 4 resected. And that'll be relevant actually as we talk about the next abstract that will come in this discussion. Dr. Diwakar Davar: Just to underscore, positive RFS data, positive DMFS data, and now this therapy has currently got regulatory approval in this investigation and is approved in the United States and certainly in Europe and Australia. One interesting point that we will probably have to contend with, and some of the listeners may be thinking about, is overall survival. So the last adjuvant study that demonstrated overall survival benefit was actually ipilimumab, and increasingly, the Illuminati in melanoma do not believe that we will ever see OS benefit in this disease going forward, even though it has to be an endpoint in all registration phase 3 trials. So, Jason, what are your thoughts about whether or not we'll have a positive OS readout, and even if we don't, why this is still a very important advance in this disease at this time? Dr. Jason Luke: Your points are well taken. I think it's unclear, probably trending towards unlikely, that we would see an overall survival advantage in this trial given that we have not seen that in the stage 3 adjuvant studies. Now people can debate if, whether or not overall survival is the only meaningful endpoint for patients. I personally do not believe that's true. And to me, preventing recurrence has a value in and of itself, whether or not that's connected to overall survival. And part of the reason that I say that is that for an average patient, the median patient on a trial, of course, we can tell them treatment now, treatment later. It's a wash when you look at the overall study. And yet at the same time, for an individual person who's facing melanoma or cancer, generally they're not going to be the average patient; they're going to be one patient. And it's very possible they could end up with the type of recurrence that in fact is not highly treatable at that time. So I think that's really the nuance that goes into those adjuvant discussions. The regulatory endpoints have been recurrence in melanoma for a long time. And I think it's important that patients understand the pros and the cons of each. The complexity in adjuvant therapy and neoadjuvant therapy is you don't necessarily know that you had to have it. You're only really going to know whether or not it didn't work if you recur later on. But to me and in my clinic, most patients are willing and interested to want to pursue those therapies in the perioperative setting to try to reduce the possibility of ever developing metastatic disease. Dr. Diwakar Davar: Excellent. So I think key advance [is] positive DMFS data to add to the earlier reported RFS data and truly practice-changing. So, moving on to the next study, LBA9503. This is the phase 2 trial of the Moderna vaccine. This is the trial that almost every medical oncologist knows intimately or has been called about by either the press or patients. So what is this study? This essentially is a phase 2 trial evaluating the personalized cancer vaccine PCV Moderna, made by Moderna, the mRNA vaccine, that is being studied in combination with anti-PD-1 pembrolizumab in the stage 3 BCD and stage 4 resected setting. And so there are really two very interesting results here because this is an update of the RFS data that was presented at AACR earlier this year, which was positive. What are your takes on the DMFS results, and maybe a quick blurb on how is this vaccine generated for those who may not be aware of this particular platform? Dr. Jason Luke: Yeah, certainly. So this individualized neo-antigen therapy, as we're now calling it, is a technology platform that allows us to develop an individualized treatment for each patient based on their own cancer. So taking the actual tumor specimen, whole exome sequencing is performed to try to identify changes in the DNA, and then through a reasonably complex bioinformatic pipeline, those mutations that are likely to generate proteins that can be bound within class 1 MHC molecules are then identified in the computer and then synthesized with an mRNA, very similar to the way that the COVID vaccines were made. And then that becomes the actual drug. So in the clinical trial, which was KEYNOTE-942, about 160 patients were randomized 2 to 1 to receive either pembrolizumab for a year as per standard adjuvant therapy but then with the addition of the individualized neoantigen therapy starting with dose 3 and throughout the rest of the year versus the control arm of pembrolizumab as the standard of care. As you mentioned, the recurrence-free survival were highly positive in this trial when it was first presented earlier this year, and at the updated ASCO we see the 18-month RFS in which the hazard ratio continues to be maintained. But I think most impressively is that distant metastasis-free survival, where we saw an even greater advantage for distant metastasis-free survival – hazard ratio here being 0.35. And so that's a huge advantage for distant metastasis-free survival in this population of patients. And very interestingly in the clinical trial, when you follow the Kaplan-Meier plots, what you see over time is that they overlap almost the entire first year. And it's really at about a year, basically after the vaccine has had time to kick in and these neoantigens have been identified, that we then start to see the separation of the curve, which looks very flat over time. And so I think this is a very, very exciting kind of technology platform and very exciting results because there was minimal increase in toxicity – just at the site of the local injection – for the addition of the individualized neoantigen therapy. And beyond that, hypothetically, this is not necessarily just a melanoma thing. So, of course, based on these phase 2 results, a phase 3 clinical trial called KEYNOTE-V940 is going to be launching later this year to compare pembrolizumab versus pembrolizumab plus this V940 individualized neoantigen therapy. And we're very, very excited in the field to see what those results will look like because the concept here is you could really, really enhance adjuvant therapy with this kind of an approach. Meanwhile, we're just about to talk in a little bit about all the exciting things happening in the neoadjuvant space as well. And with no increase in toxicity, obviously, that looks really good. Suffice it to say that this technology is not specific to melanoma but rather could be applied almost to any cancer where we think about an adjuvant therapy platform. So I think the results are very, very exciting. It is a phase 2 study and it does have some caveats about not being the largest study and some other things, but you can't help but be impressed by the data that have been presented here so far. Dr. Diwakar Davar: One important plug, I guess, in addition to that is that you mentioned that there's data using the platform in other diseases. And one really exciting paper that came out recently was Dr. Vinod Balachandran's paper; for those who haven't read it, it's in Nature, and really in a very provocative proof of concept study, they studied the platform, the vaccine plus checkpoint inhibitor therapy plus chemotherapy in a highly adverse tumor patient population. So these are patients with resectable pancreatic cancer who had the vaccine generated from pancreatic cancer that was resected after Whipple surgery. And extraordinarily, out of the 16 patients who had immune responses, 8 of them did not have relapse at a median follow-up of almost a year and a half, which is really quite extraordinary given the lack of really any effective drug outside of chemotherapy in that setting. So, the point that you're making regarding the benefit of this therapy, suggesting that it could potentially be extended to not just melanoma, potentially other tumors such as highly immunogenic tumors, and potentially even nonimmunogenic tumors such as pancreatic cancer, really suggests that this is going to be a very exciting landscape. And potentially this area, adjuvant therapy and neoadjuvant therapy, like we'll talk about, is potentially an area in which other drugs and potentially combinations will be developed. So next, we will be discussing 3 abstracts evaluating the theme of combinations, and these abstracts are 9501, 9502, and 4010. Abstract 9501 is an evaluation of the combination of fianlimab and cemiplimab anti-LAG-3 and anti-PD-1, respectively, in advanced melanoma, specifically focusing on the post-PD-1 experience in this disease by Dr. Omid Hamid. 9502 is the updated 2-year survival results from RELATIVITY-047, which evaluated nivolumab and relatlimab against nivolumab alone in frontline metastatic melanoma. And Abstract 4010 are the results from the MORPHEUS platform study, specifically looking at tiragolumab and atezolizumab in patients with advanced unresectable HCC. But focusing on 9501 and 9502, Jason, what do you make of the combination of fianlimab and cemiplimab post-PD-1 setting? Dr. Jason Luke: I think the data look very intriguing for this second combination of PD-1 and LAG-3 combination. When nivolumab and relatlimab, the approved LAG-3 inhibitor, kind of burst on the scene a couple of years ago, it was somewhat to the surprise of a lot of people in the community who had really come to think that while PD-1 and CTLA-4 were core molecules for therapeutics and cancer, that we just weren't ever really going to see something else come along in checkpoint blockade. And so nivo and rela got approved. We'll talk about them again in a second. But the data now coming forward for another PD-1 LAG-3 combination, again with cemiplimab PD-1 and fianlimab LAG-3, looks very, very promising. So in Abstract 9501, they updated a phase 1 expansion cohort, phase 2 cohort looking at patients across the various different settings. And whereas in the treatment naive frontline metastatic setting they had previously described about a 63% response rate, they saw a similar level of response rate in patients who had previously gotten adjuvant anti-PD-1, had a period of time off treatment, and then were treated again. And that was reassuring because it suggested that this is still an active combination even with prior exposure to IO in the past. Now, the thing that I found to be the most interesting about this combination was whereas with nivo and rela, at least from the RELATIVITY-047 phase 3 trial, it looked like there was less benefit in some of the high-risk population cohorts, at least for this combination in early testing for cemi and fian; like we talk about it sometimes, we saw there was a high response rate even in patients with liver metastases and some other high-risk features. And so I think this combination looks quite potent, and I'm very excited to see what the data will look like. I think it's very unlikely we'll ever actually get a randomized trial of two PD-1 LAG-3 combinations against each other. But suffice it to say that the data we've seen so far for fianlimab LAG-3 with cemiplimab PD-1 looks very intriguing. It certainly justifies the frontline metastatic phase 3 and the adjuvant phase 3 trials that are already in planning or ongoing. Dr. Diwakar Davar: So one thing to consider is on the RELATIVITY-020 trial – the early trial that was led by Dr. Ascierto that really took a long time to read out – the response rate in patients with prior checkpoint inhibitor therapy was quite low. In fact, the data was quite surprising, as you'd mentioned that we had even seen this movement in the frontline setting because the response rate by BICR was only about 12%. So do you feel like the 2 LAG-3 inhibitors are fundamentally different? And if so, can you speculate as to why that might be? Again, with the caveat to the fact that these are very early data and we don't have enough information. And maybe we can also talk a little bit about the 2 pending trials that are ongoing in the advanced and adjuvant therapy landscapes perspective. Dr. Jason Luke: I think we don't have enough data yet to truly understand whether or not they're really different. The trials that have been run so far are so different that it's hard to compare things back and forth. You can notice that the dose, the milligram dosage of fianlimab in terms of anti-LAG-3 is quite a bit higher, like a log fold higher almost than with relatlimab. And so there's some question of whether or not just merely more drug-blocking LAG-3 might in fact be more efficacious relative to the dose that's approved for relatlimab in melanoma. But beyond that, I think the data hold up very well for this new combination, again noting all the caveats about cross-trial comparison to, say, it looks to be at least as potent, possibly more potent than the relatlimab combination. But again, I think probably we need to see the data from randomized trials and how that fits into the landscape when the trials actually read out because there's a lot of things going on in melanoma that are likely to change between now and then. Dr. Diwakar Davar: So just to draw people's attention, there are actually 2 ongoing pivotal phase 3 trials: fian plus cemi versus pembro in patients with advanced metastatic and locally advanced, previously untreated melanoma, as well as an adjuvant trial of the combination against pembrolizumab. Again, highly high-risk resected melanoma. These trials are ongoing. We don't have the results yet and we are looking forward to them. Now, 9502, a 2-year RELATIVITY-047 result presented by Dr. Hussein Tawbi. Dr. Jason Luke: So this is the study we were just alluding to before, the randomized phase 3 study of nivolumab versus nivolumab plus for relatlimab. To me, the most useful data sort of updating with this two-year survival follow-up is to show the maintenance of benefit between the 2 arms. And so, consistent with what we saw with nivolumab and ipilimumab, there seems to be a persistent delta between the arms for both progression-free and for overall survival out over that extended period of time, where we can see with that updated data now, at 2 years, that it's 52% of patients still alive on the relatlimab combo versus 42 with nivolumab. And it does seem like this is probably a higher-risk population of patients than participated in CheckMate-067. So it's a little bit difficult to compare the landmarks except to notice that that difference between the control and experimental groups is consistent over a long period of time and that there were no new safety signals either, and so that was also reassuring. To me, the most interesting nugget of data in the abstract, though, is to look at what happened to patients after they were on the first-line treatment. So one of the big questions in our field is really “If patients get nivolumab and relatlimab upfront, what should they get after that?” Should they then get nivo plus ipi, or vice versa? And I think we don't have an answer clearly to that question just yet. There was an important letter to the editor of the New England Journal now going on about a year ago by Alex Menzies and colleagues that suggested that the use of ipilimumab was attenuated, the utility of it, after a prior exposure to nivolumab plus relatlimab. They quoted a response rate on the order of only about 10% for patients who got an ipilimumab-containing regimen after initial LAG-3. In the data from Hussein Tawbi at ASCO, however, in a small number of patients, caveat, the response rate was more in sort of the low 20% range, 22% to 25%. And so that would be a much more meaningful and important sort of consideration. If we do have independent activity, then lining up sequential therapies and the toxicities associated with each will become increasingly important as we think about how to maximize these kinds of treatments for our patients, but important longer-term data to show that the benefit is holding up and it's safe, and some new insights into what to do after progression on one of these regimens. Dr. Diwakar Davar: So, pivoting slightly to combinations, we are going to be discussing a combination of TIGIT plus checkpoints. So tiragolumab is the FC-active TIGIT inhibitor from Regeneron-Roche and this is currently in multiple pivotal phase 3 trials, several of which have been negative, including SKYSCRAPER-01 in non-small cell lung cancer and SKYSCRAPER-03 in small cell lung cancer. The MORPHEUS platform trial essentially is a platform study evaluating multiple different combinations, in this case in liver cancer. And so we have a very interesting Abstract 4010, which is giving us an early readout of the evaluation of tiragolumab plus atezolizumab along with bevacizumab in unresectable, locally advanced or metastatic hepatocellular carcinoma giving us a result that is a little different from what we had seen from the prior negative results of TIGIT. So Jason, what do you make of these early results in the advanced HCC setting? Dr. Jason Luke: I think these are cautiously intriguing results to really highlight the point is the third checkpoint possibly being LAG-3, now a fourth checkpoint maybe with TIGIT, but with all the caveats that you talked about. In this study, the flow is that there's a continuously accruing control arm which in hepatocellular carcinoma is a combination of atezolizumab plus bevacizumab, and then other arms are added where you add in a third agent. In this case, it's the anti-TIGIT tiragolumab. And in an intriguing fashion, the response rate to the triplet was 42.5% compared to the doublet which was only 11%. So that's a pretty big difference in this population. Now, it wasn't the largest study, only 58 patients, but it was a randomized clinical trial. And so I think those data really make people kind of open their eyes again. It's worth a little bit of a caveat here that HCC is an unusual cancer in that what is deemed to be unresectable and therefore amendable to systemic therapy is a moving target and that requires multidisciplinary evaluation of patients. And so I think a larger number of patients would really be needed to fully understand this. But certainly, a fourfold increase in the benefit or in terms of response rate looks quite intriguing. I think the other piece of this is to be just cautious a little bit was when the initial data in non-small cell lung cancer in the CITYSCAPE study came forward, and they looked roughly sort of like this: There was more than a doubling in the PFS and the response rate, which is what triggered all of those phase 3 studies. So to me, this is enough to continue to be very interested in TIGIT as a therapeutic target. And there are many phase 3 trials already ongoing. And so I think, I'm cautiously optimistic that some of those actually will be positive and we could see more movement around TIGIT becoming a standard of care agent. Dr. Diwakar Davar: To your point about TIGIT being an interesting target, recent data looking at the neoadjuvant landscape in melanoma from Merck, with Merck, also FC-active TIGIT and also some data from authors looking at that TIGIT also presented in this case at ASCO specifically from the ARC-7 study. So very interesting target. Several pivotal trials have been announced. Do you know of any trials that are ongoing in the adjuvant setting in other diseases? Dr. Jason Luke: Well, as you alluded to, the vibostolimab data in melanoma for TIGIT in the neoadjuvant setting was interesting. And in fact, that has been enough to trigger a global, randomized phase 3 adjuvant study of pembrolizumab and vibostolimab versus pembrolizumab in melanoma. And that sort of takes us back to the beginning of our discussion here, building on the KEYNOTE-716 data. So, yes, TIGIT will be moving forward in the adjuvant space in melanoma and obviously at a static setting for several different tumor types with a PD-1 or PD-L1 backbone. Dr. Diwakar Davar: So now pivoting towards neoadjuvant therapy and non-small cell lung cancer. The standard of care in this setting was established by the CheckMate-816 trial that essentially established nivolumab plus chemotherapy in the setting of resectable non-small cell lung carcinoma path. Response rate in this setting is approximately 21%. And we have several studies that are essentially looking at novel combinations or in this case, different PD-1 inhibitors in this setting. So Abstract 8500 essentially looked at nivolumab plus relatlimab from a NEOpredict-Lung trial. Jason, do you want to tell us a little bit about this? Dr. Jason Luke: Yes, I think this is a very interesting study and that this is sort of our first peek at targeting LAG-3 in the context of lung cancer. So obviously we talked about LAG-3 for melanoma. Although the audience is probably aware that there have been neoadjuvant data for LAG-3 with relatlimab in melanoma that substantiated the phase 3 data for the metastatic setting. So one of the questions as we start to apply the LAG-3 in other diseases would be, “Do we see it hold up in both metastatic disease and in the neoadjuvant space?” But in this study, while there were no changes in the safety profile; it didn't impact on whether or not patients could have surgery. There really didn't look to be a big difference in this study between nivolumab and nivolumab plus relatlimab, with the major pathologic response as you alluded to right around 30% for both arms. Now, it wasn't really the biggest study, but that's certainly quite a bit in contrast with what we've seen in melanoma, where with a PD-1 inhibitor you get again 25%-30%, but with adding on LAG-3, that pushes you up closer to 60%. So I think these were very interesting data that probably put a little bit of an eyebrow raise to say, “Well, let's see what happens in the metastatic setting in lung cancer with the addition of relatlimab LAG-3 on top of a PD-1.” I think it might not be quite so straightforward as what we saw in melanoma, but we'll look forward to those results because those phase 3 trials in metastatic lung cancer should be maturing sometime in the next year or two. Dr. Diwakar Davar: The theme of neoadjuvant therapy non-small lung cancer, LBA100, which has again previously been discussed in an episode of this podcast by Dr. Jack West and Dr. Velcheti is KEYNOTE-671. And this is a study essentially that looked at pembrolizumab or placebo with platinum-based chemotherapy doublet and followed by resection. So again, a direct parallel to CheckMate-816. What do you make of the results that were reported by our colleagues in this setting, Jason? Dr. Jason Luke: So not to rehash this, because our colleagues in the lung cancer group have already discussed this at length and obviously they're experts in that disease, but we'll just note that there was a threefold increase in major pathologic response, which turned into a major advantage for event-free survival. And so I think this is at least the third PD-1, PD-L1 combination regimen for neoadjuvant lung cancer that looks very, very promising. It certainly, to me, seems like neoadjuvant consideration really should be the standard of care already moving forward. To me, what the big question that is left with is “Do we still need the adjuvant component after we give the neoadjuvant?” So, some of the trials are including neoadjuvant and adjuvant, some of them are only neoadjuvant. And I think that's going to be a really important question as we move into the future, both in terms of what is that contribution of the adjuvant component, and then again, going back to earlier in our discussion here, if there could be a major advantage to adding individualized neoantigen therapy, maybe it is important to have both. But I think that's one of the big questions we have to get teased out by the field over the next couple of years. Dr. Diwakar Davar: And finally pivoting towards cutaneous squamous cell carcinoma. We have 2 abstracts discussing perioperative therapy. So cutaneous squamous cell carcinoma is a high-TMB tumor. The median tumor mutation burden in this disease is threefold that of melanoma. This is a disease in which checkpoint inhibitor therapy is approved as a single agent both with pembrolizumab and cemiplimab on the basis of nonrandomized phase 2 trials. And increasingly, there has been early development in the perioperative setting. The first data in this space came from our colleague Dr. Gross at MD Anderson, who reported in a small, nonrandomized phase 2 trial of 20 patients, a path CR rate with two cycles of cemiplimab at approximately 50%. A larger multi-institutional phase 2 trial demonstrated that a longer duration of perioperative therapy of four cycles or 3 months of cemiplimab did not particularly improve the path response rates. The response rates were similar at approximately 50% as well. And what we have right now are 2 other trials. The first is the MATISSE trial, Abstract 9507 ,that evaluated nivolumab or nivolumab plus epilimumab in this disease. And the other one was the NEO-CESQ trial, or Abstract 9576, that evaluated neoadjuvant plus adjuvant therapy that's cemiplimab in the high-risk patient population. So we're starting with 9507. Jason, what do you make of the ipi and ipi-nivo data reported in this setting? Dr. Jason Luke: So I think this is a really interesting study because I think part of the intent is the clinical aspect of how you manage patients with cutaneous squamous cell carcinoma. For those that don't do cutaneous oncology, many of these patients have the development of lesions, which can be actually quite difficult to resect in a way that's not otherwise mutilating or cosmetically quite problematic. And that was part of the impetus for this trial where, again, they looked at either monotherapy PD-1 or a PD-1 plus CTLA-4, and they saw great success. As was predicted based on the other data that you alluded to, response rates are more than 50% near 60%, with actually a substantial number of patients on the trial actually refusing to have surgery after they received their neoadjuvant therapy because they were so certain that they had had a good outcome. So I think these data are quite reassuring in the context of all of this emerging data around cutaneous squamous cell carcinoma. We'll talk about this NEO-CESQ trial in just a second, but I think it really is emerging to be the standard of care very soon for the use of perioperative PD-1 for cutaneous squamous cell. Dr. Diwakar Davar: What do you feel about the dose and schedule of checkpoint inhibitor therapy used here? So the dose of ipilimumab used was ipi-1 and not ipi-3, and they waited 4 weeks. So when patients only got two cycles of Q2 weekly nivo, and one cycle of ipilimumab, do you think the responses would have been deeper if they'd waited longer? Dr. Jason Luke: I think it is possible that they might have been deeper, although I'm not totally sure about that. One of the other abstracts we're not directly mentioning here was a study in Merkel cell carcinoma which suggested that in fact, adding ipi and that also highly immuno-oncology-responsive tumor type did not add to the response rate. So I'm not totally sure about that. I think rather what would be most interesting here is sort of the sort of next generation of biomarker work. As part of their presentation, the MATISSE trial team showed gene expression profiling that really strongly identified which patients were going to do well on the trial. And I think that's probably eventually going to be how we need to think about this. There are patients in the neoadjuvant setting who are going to do really well with anti-PD-1 alone. And then for those who aren't, that's where we probably really need to think about do we need combos, how long to give the treatment, etc. And I think we're really only on the cusp in the beginning of this, which is exciting as we think about moving into the future. Dr. Diwakar Davar: Certainly, many combinations are being evaluated in this space and we are very excited for the data that it's about to hopefully come in the next couple of months to years. So the NEO-CESQ – it's quite a puzzle as to how to pronounce this acronym – and this evaluated cemiplimab in the high-risk setting. So it's worthwhile noting that Dr. Gross's first trial looked at high-risk stage 2, 3, and 4 disease. So the context of cutaneous squamous cell carcinoma that's node-positive disease and distant metastatic disease that is in one location or patients with node-positive disease invention. And his multi-institutional cemiplimab trial of four cycles evaluated included patients with stage 2, 3, and 4 disease. So here in a study just in stage 3 and 4 diseases, Dr. Ascierto reported the results of 2 cycles of cemiplimab and importantly, these patients had both the neoadjuvant and the adjuvant portion of cemiplimab. So, Jason, you mentioned earlier that one of the key aspects that we start thinking about neoadjuvant therapy is exactly how much do you need. Do you need both the pre-surgical therapy and the post-surgical therapy? Is the presurgical therapy enough? After all, neoadjuvant response equals cure. How much benefit are you getting from post-surgical portions? So what do you make of the results that they've seen here and what is the impact? How do you think we'll be disentangling the impact of the neoadjuvant and the adjuvant portion of the immunotherapy upon response and survival? Dr. Jason Luke: So just to leverage those comments, I think these data are reassuring because in this higher-risk group of patients, they saw excellent outcomes very similar to what Gross et al had previously reported. So that's good. To your question about how we are going to disentangle this adjuvant versus non-adjuvant question, there's a trial in melanoma called the NADINA trial which is ongoing now in which the use of the adjuvant therapy is actually risk-adapted. So after patients have an initial neoadjuvant treatment they're evaluated, and if they have had a pathologic complete response, they're actually going to stop that treatment and they're not going to give the neoadjuvant therapy. And so I think obviously it's a slightly different disease, but those kinds of data, I think, will be very meaningful to help us sort this out. And I'm not sure whether or not in cutaneous squamous we would need a different trial than in melanoma, although I think in a different tumor, maybe like, say, lung cancer, you probably would need a dedicated study to try to look at that because I think just the responsiveness to checkpoint blockade is going to vary quite a bit once you get outside of cutaneous oncology. But to summarize, reassuring that a similar pathologic response rate, and I think this question of adjuvant or nonadjuvant, I think that's the next question we've got to answer in the field. Dr. Diwakar Davar: We have now come to the end of our back-and-forth discussion on these very, very exciting abstracts. So Jason, thank you for highlighting these advances and for engaging in a robust discussion. Dr. Jason Luke: Thanks for having me. Dr. Diwakar Davar: And thank you to our listeners today for taking the time to listen to this podcast. You will find the links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear in the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Diwakar Davar @diwakardavar Dr. Jason Luke @jasonlukemd Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Diwakar Davar: Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences Consulting or Advisory Role: Instil Bio, Vedanta Biosciences Consulting or Advisory Role (Immediate family member): Shionogi Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences Research Funding (Inst.): Zucero Therapeutics Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical , Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio
In this week's “Throwback Thursday / Where are they now?” segment, we hear from a Shopify seller who earns passive income every day from sales of his city art prints. He'll tell you how he did it, how he decided on pricing, and how he markets the business *without* using social media. Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Twitter: @chrisguillebeau Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.
You've played this game before but this time it's different. The neon cityscape is glitching, go [left] or [right]. Music/sounds from Epidemic SoundFind The Fairy Ring on Instagram here.
Join Drew Breneman as he welcomes back Gabe Horstick, founder of Base 3, a real estate investment company. In this episode, Gabe shares insights on:- Chicago's accessory dwelling unit ("ADU") ordinance- How he has grown his business- His latest development in Lincoln Park- How rent increases in Chicago, have allowed him to beat revenue projections by nearly 10% across his portfolio. - CityScape program he uses to consolidate data and make informed investment decisions.He also shares tips on making money in real estate and discusses the lessons he's learned over the years as a multifamily investor. To contact Gabe, visit his company at https://base3co.com/--Real estate is the most proven way to build wealth. But learning how to invest in real estate is not easy. You need a blueprint from other successful investors. That is what this podcast is all about.In each episode, join Drew Breneman, a real estate investor who owns more than $200M in property, as he and his guests teach you what you actually need to know to be a successful investor. Whether you are a full-time active investor, a passive investor, close to retiring, just starting out, simply looking for an alternative to the stock market, this podcast is for you.His company, Breneman Capital, is a private real estate investment management firm specializing in the multifamily property sector. Breneman Capital employs a deliberate investment approach, leveraging data analytics and proprietary technology to generate superior risk-adjusted returns for investors.Breneman Capital has developed an investment strategy that aims to exploit market inefficiencies and reveal superior risk-adjusted opportunities through comprehensive use of technology and analytics.Get started today as an investor or learn more at: https://www.breneman.com--Follow Drew on Social:Twitter: https://twitter.com/drewbreneman LinkedIn: https://www.linkedin.com/in/drewbreneman
Return guests Casey Smagala and Steven Vance of Chicago Cityscape join us to discuss the revised Transit-Oriented Development (TOD) ordinance and other development trends in Chicago! Casey and Steven start off by explaining the TOD ordinance and the changes resulting from the recent revision. They dive deep on the impacted neighborhoods, zoning districts, and provisions of the ordinance. Casey and Steven showcase their urban planning backgrounds by weighing in on the impact of current city policies and how they would improve those policies. Lastly, they share why Cityscape is such a powerful data-aggregation software and how it can give Chicago Investors a tremendous competitive advantage! If you enjoy today's episode, please leave us a review and share with someone who may also find value in this content! Connect with Mark and Tom: StraightUpChicagoInvestor.com Email the Show: StraightUpChicagoInvestor@gmail.com Guest: Casey Smagala and Steven Vance, Chicago Cityscape Link: SUCI Ep 97 - Samuel Pavlovcik Link: SUCI 112 - Cityscape (1st Episode) Link: SUCI Ep 59 - Cost-Seg Kev Link: The New Localism (Book Recommendation) Link: UCLA Housing Voices Podcast Sponsors: Essex Realty Group and Appeal.tax ----------------- Guest Questions 03:18 Housing Provider Tip: Use online services by Utility providers to expedite requests! 06:14 Intro to our guests, Steven Vance and Casey from Chicago Cityscape! 07:00 What is the TOD ordinance? 10:26 Who can benefit from the revised TOD ordinance? 13:22 Steven and Vance talk about accessible dwelling units! 16:34 Are there de-conversation limitations within the revised TOD ordinance? 18:52 Steven and Vance talk about neighborhoods most impacted by the ordinance! 26:31 How does the ordinance affect parking requirements? 31:53 How do City policies attempt to control density? 38:00 What policy changes can investors expect in the near future? 39:50 How does the City measure the success of their new policies? Wrap Up Questions 43:12 What is Casey's and Steven's competitive advantage? 43:58 One piece of advice for new investors. 48:22 What do you do for fun? 49:18 Good book, podcast, or self development activity that you would recommend? 51:24 Local Network Recommendation? 54:21 How can the listeners learn more about you and provide value to you? That's our show! Thanks for listening! ----------------- Production House: Flint Stone Media Copyright of Straight Up Chicago Investor 2022.
Photo: [Johnstown, Pa.:. Cityscape photograph @Batchelorshow 2/4: The migrants of Johnstown PA. Russell Shorto. Smalltime: A Story of My Family and the Mob. Hardcover – February 2, 2021, by Russell Shorto (Author) https://www.amazon.com/Smalltime-Story-My-Family-Mob/dp/0393245586/ref=tmm_hrd_swatch_0?_encoding=UTF8&qid=&sr= Family secrets emerge as a best-selling author dives into the history of the mob in small-town America. The best-selling author Russell Shorto, praised for his incisive works of narrative history, never thought to write about his own past. He grew up knowing his grandfather and namesake was a small-town mob boss but maintained an unspoken family vow of silence. Then an elderly relative prodded: You're a writer―what are you gonna do about the story? Smalltime is a mob story straight out of central casting―but with a difference, for the small-town mob, which stretched from Schenectady to Fresno, is a mostly unknown world. The location is the brawny postwar factory town of Johnstown, Pennsylvania. The setting is City Cigar, a storefront next to City Hall, behind which Russ and his brother-in-law, “Little Joe,” operate a gambling empire and effectively run the town. Smalltime is a riveting American immigrant story that travels back to Risorgimento Sicily, to the ancient, dusty, hill-town home of Antonino Sciotto, the author's great-grandfather, who leaves his wife and children in grinding poverty for a new life―and wife―in a Pennsylvania mining town. It's a tale of Italian Americans living in squalor and prejudice, and of the rise of Russ, who, like thousands of other young men, created a copy of the American establishment that excluded him. Smalltimedraws an intimate portrait of a mobster and his wife, sudden riches, and the toll a lawless life takes on one family.
Jiries Dawaher graduated high school in 2002 with a GPA of 1.53. He then served in the Army National Guard in Ohio as a helicopter and diesel mechanic for nine years, dabbling in network marketing on the side. After getting out of the military, he was bartending in Hilton Head, SC, when he got a call from a friend who was making money by wholesaling in Cincinnati — and the rest is history. In this episode, Jiries shares about using his wholesaling background to acquire multifamily properties, his top networking strategies, and how he ventured into the hotel business. Jiries Dawaher | Real Estate Background Owner of JDS Holdings IX LLC and Homes by CityScape, which buys and renovates homes from single-family to multifamily to rent. Portfolio: GP of 51 units and two hotels Based in: Cincinnati, OH Say hi to him at: Instagram Facebook Linkedin His book: Real Estate Investing 101: How You Can Go From Broke to 7 Figures in Five Simple Steps Greatest lesson: Surround yourself with people better than you. Click here to know more about our sponsors: Cash Flow Portal | Cornell Capital Holdings | PassiveInvesting.com
© 2020-2025 Ivy Podcast Discovery LLC
